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Background: There are no completed randomised trials of the use of corticosteroids in patients with
severe influenza infection. Corticosteroid use in influenza is widespread, non-systematic and marked by
controversy. A recent meta-analysis of observational studies of adjuvant corticosteroids in influenza found
an association with increased mortality but there were important concerns regarding the risks of bias.
Objectives: To (1) evaluate whether or not low-dose corticosteroids given as an adjunct to standard
treatment is beneficial in patients who are hospitalised with severe pandemic influenza and (2) develop an
‘off-the-shelf’ clinical trial that is ready to be activated in a future pandemic.
Design: Multicentre, pragmatic, blinded, randomised placebo-controlled trial.
Setting: Thirty to 40 hospitals in the UK.
Participants: Adults (≥ 16 years) admitted to hospital with an influenza-like illness during a pandemic.
Intervention: Five-day course of dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) 6mg daily,
started within 24 hours of admission.
Main outcome measure: Admission to Intensive Care Unit, or death, within 30 days of admission
to hospital.
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Results: This trial has not yet been activated. It is currently set up with full ethics and regulatory approvals
in place, ready for rapid activation at the onset of the next pandemic. Hurdles to setting up a pandemic
trial include planning for pandemic-level pressures on UK NHS resources and co-enrolment of patients to
multiple pandemic studies, ensuring adequate geographical distribution of participating sites, maintaining
long-term low-level engagement with site investigators, addressing future trial-specific training needs of
local investigators and resilience planning in trial management. Identified threats to trial delivery include
changes to research capabilities or policies during the hibernation phase, lack of staff resources during a
pandemic and the influence of media at the time of a pandemic. A mismatch in the approach to informed
consent required by current regulations to that preferred by patients and the public was identified.
Conclusions: This study demonstrates that advance set-up of a trial to be conducted during a pandemic,
with full regulatory approvals in place, is possible. Regular review during the hibernation phase will be
required. This study serves as a model for the development of other ‘off-the-shelf’ trials as part of
preparedness planning for public health emergencies.
Trial registration: Current Controlled Trials ISRCTN72331452. European Union Drug Regulating
Authorities Clinical Trials number: 2013–001051–12.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 16.
See the NIHR Journals Library website for further project information.
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Plain English summary
The aims of this study are to (1) find out whether a commonly used steroid (a medicine that reducesinflammation) called dexamethasone, given in addition to the normal treatment for flu, will benefit
patients admitted to hospital with flu during a pandemic and (2) set up a trial in advance of a pandemic,
which can be put into ‘hibernation’ for rapid activation when required.
The trial will be conducted at approximately 40 hospitals in the UK. Adults admitted with flu in a pandemic
will be asked to take part. Participants will be randomly given either a 5-day course of dexamethasone or
a matching placebo (dummy medicine without any active ingredients). Information recorded routinely in
patients’ medical notes will be used to determine whether or not treatment with dexamethasone reduces
the number of patients who die or are admitted to intensive care within 30 days of hospital admission.
The challenges encountered during set-up included:
(a) planning for a period when health-care resources will be exceptionally stretched
(b) ensuring geographical spread of participating hospitals
(c) addressing future training needs of investigators
(d) resilience planning of trial management.
Patients and the public were found to prefer arrangements for giving their consent which current
regulations do not permit. Whether or not this will create difficulties in future remains to be determined.
This study demonstrates that advance set-up of a trial with full regulatory approvals in place, is possible;
it serves as a model for the development of other ‘off-the-shelf’ trials in public health emergencies.
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Scientific summary
Background
The use of corticosteroids in patients with severe sepsis is recommended by international sepsis guidelines.
This recommendation is based on evidence from numerous randomised controlled trials and subsequent
meta-analyses. In patients who are hospitalised with community-acquired pneumonia, a recent
meta-analysis of randomised controlled trials reported a survival benefit from corticosteroid therapy
in the subgroup of patients with severe pneumonia. Further large clinical trials are ongoing in the fields
of both severe sepsis and community-acquired pneumonia to investigate the role of corticosteroids as
adjuvant therapy.
In contrast, there are no completed randomised trials of the use of corticosteroids in patients with
pandemic, avian or seasonal influenza infection. Corticosteroid use in influenza is widespread,
non-systematic and marked by controversy. A recent meta-analysis of observational studies of adjuvant
corticosteroids in influenza found an association with increased mortality but there were important
concerns regarding the risks of bias.
Objectives
The aims of the Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial are to (1) determine
whether or not low-dose corticosteroids, given as an adjunct to standard treatment, are beneficial in
patients who are admitted to hospital with severe pandemic influenza, and (2) demonstrate that an
‘off-the-shelf’ model for a trial that is designed, set up and ready to activate during a public health
emergency is possible.
Methods
The trial study design and planned analyses are described below. Methodological aspects of trial set-up
and delivery that are unique to the ‘off-the-shelf’ nature of this study are reported in the next section
(see Results).
This is a pragmatic blinded, randomised placebo-controlled trial to determine whether or not during a
pandemic, for adults (≥ 16 years) who are admitted to hospital with an influenza-like illness, a 5-day
course of dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) started within 24 hours of admission,
in addition to standard care, is associated with a lower risk of death or admission to intensive care than
placebo. This trial will be conducted at 30–40 sites across the UK during the first wave of the next
influenza pandemic and will recruit 2200 participants, probably over a 6-week period.
Adults with a clinical diagnosis of an influenza-like illness at the time of hospitalisation will be eligible
for recruitment to the ASAP trial; a laboratory diagnosis of influenza will not be required. The definition
of an influenza-like illness will be confirmed at the start of the pandemic and will conform to the
definition provided by Public Health England at the time. Adults who are known to be taking or requiring
corticosteroids at the time of hospitalisation, and those who are on medication for the treatment of
diabetes mellitus, will not be eligible to participate in the trial.
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The study intervention is dexamethasone, administered as an oral liquid preparation, 6mg once daily for
5 days. Dexamethasone 6mg is equivalent to prednisolone 40mg or hydrocortisone 160mg. The study
control is a matching placebo, identical in colour, taste and consistency to the intervention. Participants will
be randomised (1 : 1 ratio) to receive dexamethasone or placebo. In addition to the intervention/placebo,
all patients will receive standard care for influenza, including oxygen supplementation, fluids, antiviral
drugs and antibiotic drugs as appropriate.
In a high-severity pandemic, the primary composite outcome is admission to intensive care or death by
day 30. In a low- to moderate-severity pandemic, the primary outcome is time to hospital discharge.
A planned early analysis focused on the primary end points will be performed to provide rapid data to the
UK Department of Health prior to the start of the second pandemic wave. Pre-planned subgroup analyses
will be conducted for the primary outcome, based on the following baseline factors:
1. duration of symptoms
2. clinical diagnosis of pneumonia
3. underlying comorbid illness
4. severity of influenza.
In parallel with the ASAP trial, we have set up a mechanistic substudy to be conducted at six pre-selected
trial-participating sites. The substudy will collect biological samples from 200 ASAP trial participants to
determine the interaction of steroid therapy and the host, and to apply this in interpreting the clinical
outcomes measured. Two blood samples and one nasal swab for subsequent transcriptomic and
microbiological testing will be obtained from participants at baseline and 48 hours post first dose of
ASAP trial medication.
Results
This trial has not yet been activated. The status of the trial at the end of the set-up phase is described,
together with results from patient and public involvement (PPI) consultation events and hurdles
encountered during trial set-up.
Consultations with patients and the public specifically in relation to the consent process for this trial
included events with representatives from charitable organisations related to respiratory disorders, PPI
representatives of the East Midlands Collaboration for Leadership in Applied Health Research and Care,
a library reading group and members of a town council. The majority view from these consultations was a
preference for a clear verbal consent process prior to trial enrolment in contrast with a weightier written
consent approach; of 42 persons consulted, only two preferred a written consent approach. Initial opinions
from a Research Ethics Committee (REC) also favoured a verbal consent approach. However, current legal
regulations required a process of written informed consent for this trial.
This trial has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA)
(European Union Drug Regulating Authorities Clinical Trials 2013–001051–12) and the South Central –
Oxford C REC (13/SC/0436). Global governance checks have been completed in England, Wales and
Scotland, enabling sites to issue local UK NHS permissions. The study is registered, with the International
Standard Randomised Controlled Trial Number (ISRCTN) registry and will be conducted in accordance with
the principles of the Declaration of Helsinki, the standards of Good Clinical Practice (as defined by the
International Conference on Harmonisation) and UK regulatory and ethical requirements.
SCIENTIFIC SUMMARY
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Owing to the lengthy hibernation period, MHRA approval was granted on the condition that a substantial
amendment is submitted at the time of activation to confirm that there is no change to the risk–benefit
analysis of the trial. The requirement for an annual Development Safety Update Report (DSUR) was waived
by the MHRA. In place of this, an annual letter will be sent advising of any changes in risk–benefit analysis
of the trial until the trial is activated. Standard DSUR submissions will commence once the trial has
been activated.
Twenty-nine sites have been granted NHS site permission and a further 11 sites are in the process of
obtaining local approvals (data as of 22 January 2015). These sites cover a wide geographical area across
the UK, including most major cities. Trial activation will be at the request of the National Institute for
Health Research (NIHR). It is anticipated that recruitment will be completed by the end of the first wave of
the pandemic.
The biggest challenge in setting up this trial has been the uncertainty regarding the timing and severity of a
future influenza pandemic. Hurdles encountered during trial set-up included (1) planning for pandemic-level
pressures on NHS resources; (2) agreeing to co-enrolment of patients to other non-interventional cohort
pandemic studies; (3) ensuring adequate geographical distribution of participating sites; (4) maintaining
engagement with site investigators with respect to a trial that may not be activated for some years;
(5) addressing future trial-specific training needs of local investigators; and (6) resilience planning in
trial management.
Identified threats to trial delivery include changes to research capabilities or policies during the hibernation
phase and lack of staff resources during a pandemic. Timely and sufficient support by Comprehensive
Local Research Network units at all participating sites, not least through the redeployment of research staff
during the pandemic, will be critical to the successful delivery of this trial.
Conclusions
This is the first multicentre clinical trial that has been set up – to our knowledge – in readiness for rapid
activation at the onset of a pandemic. Advance set-up of a pandemic trial with full regulatory approvals in
place enables the resolution of many issues at an early stage, outside the ‘heat’ of a pandemic. This study
serves as a model for the development of other ‘off-the-shelf’ trials as part of preparedness planning for
public health emergencies.
Trial registration
This trial is registered as ISRCTN72331452.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the NIHR.
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Chapter 1 Introduction
Influenza virus infection is associated with a wide spectrum of illness, from no symptoms to pneumoniaand death. During a pandemic, most people are likely to experience a minor influenza-like illness,
characterised by fever and cough, typically lasting 7–10 days. For pandemic planning purposes, the UK
Pandemic Influenza Preparedness Strategy 2011 recommends that an estimated 1–4% of symptomatic
patients should be expected to require hospital care.1 Patients may be admitted to hospital either because
of influenza-related exacerbations of underlying co-existing illnesses, such as chronic obstructive pulmonary
disease or as a result of complications of influenza infection, such as pneumonia.
Following hospital admission, some patients deteriorate rapidly (within 24 hours) and require Intensive
Care Unit (ICU)-level support for respiratory failure. The proportion who might require ICU support in a
pandemic is difficult to predict and a range of 15–25% of hospitalised patients has been suggested.1
In a high-severity pandemic, resource limitations will probably define the upper limit. In the low-severity
pandemic of 2009, 17% of hospitalised patients were admitted to level 2 or level 3 care; the median time
from symptom onset to ICU admission was 6 days, and from hospital admission to ICU admission was
2 days. Overall, 7% of hospitalised patients with confirmed H1N1 influenza infection died.2
Current principles of therapy in the management of adults admitted to hospital with pandemic influenza
infection include appropriate fluid replacement, oxygen supplementation, antiviral therapy and organ
support, as required.3 In addition, antibiotic therapy is recommended for all hospitalised adults except
previously well adults with only influenza-related acute bronchitis.
Corticosteroids in influenza
The role of corticosteroids in severe influenza infection remains uncertain. During the early phase of illness,
influenza A virus infection induces inflammatory [e.g. interleukin 6 (IL-6), IL-8] and T-helper type 1
cell immune responses [e.g. interferon-induced protein 10, monokine induced by interferon-gamma (MIG)],
correlating with clinical illness.4 Hypercytokinaemia is also recognised in patients with H5N1 influenza
infection (e.g. IL-6, IL-10, MIG) with the highest levels found in patients who subsequently die.5 Similar
changes have been observed in patients with 2009 pandemic H1N1 infection.6 Such inflammatory
cytokines may suppress the hypothalamic–pituitary–adrenal axis, resulting in relative adrenal insufficiency
or competing with intracellular glucocorticoid receptor function, resulting in peripheral tissue steroid
resistance.7 In patients with septic shock and community-acquired pneumonia, corticosteroids in low doses
(e.g. hydrocortisone ≤ 300mg per day or dexamethasone ≤ 11.25mg/day) downregulates proinflammatory
cytokine transcription and has been shown to improve innate immunity.8–10
In clinical practice, corticosteroid use in influenza is widespread, non-systematic and marked by
controversy.11,12 During the 2009 pandemic, corticosteroid use in critically ill patients with H1N1 influenza
was identified in 83 (40%) of 208 patients in a French registry, 107 (44%) of 245 patients in a
South Korean cohort study, and 126 (57%) of 220 patients in the European Society of Intensive Care
Medicine H1N1 registry.13–15 The heterogeneity of these cohort studies and non-randomised study designs
preclude any firm conclusions regarding the risks or benefits of corticosteroids in the treatment of
influenza. A recent meta-analysis of observational studies of adjuvant corticosteroids in influenza found an
association with increased mortality but there were important concerns regarding the risks of bias – in
particular, bias arising from confounding by indication (corticosteroids prescribed in the sickest patients as
a ‘treatment of last resort’).16 No completed randomised trials of the use of corticosteroids in patients with
pandemic, avian or seasonal influenza infection were identified.
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Corticosteroids in pneumonia and sepsis
In patients who are hospitalised with community-acquired pneumonia, trials of adjuvant corticosteroids have
reported significant reductions in median length of hospital stay and faster declines in C-reactive protein levels
and defervescence.17,18 In 2011, a Cochrane systematic review of systemic corticosteroid use in all-cause
pneumonia reported no overall mortality benefit, but a reduction in time to resolution of symptoms: in the
subgroup of individuals with severe pneumonia, a reduction in the need for mechanical ventilation and
improved oxygenation was found.19 A more recent meta-analysis,20 which included additional randomised
controlled trials, reported a survival benefit from corticosteroid therapy in the subgroup of patients with severe
pneumonia. Currently, three large randomised controlled clinical trials investigating the effectiveness of
adjuvant corticosteroids in community-acquired pneumonia are recruiting; the interventions being tested are
prednisolone 50mg daily for 7 days (ClinicalTrials.gov identifier: NCT00973154), dexamethasone 6mg daily
for 4 days (ClinicalTrials.gov identifier: NCT01743755) and methylprednisolone 40mg/kg daily in tapering
doses over 20 days (ClinicalTrials.gov identifier: NCT01283009).
In adults with septic shock, international sepsis guidelines recommend that low-dose corticosteroids may
be considered if fluid resuscitation and vasopressor therapy are inadequate to restore haemodynamic
stability.21 This recommendation is based on different strands of evidence, including the results from
numerous randomised controlled trials and subsequent meta-analyses. In one systematic review22 of
12 randomised trials examining the benefit of low-dose corticosteroids [hydrocortisone ≤ 300mg per day
(equivalent to dexamethasone ≤ 11.25mg/day)] for ≥ 5 days compared with placebo in adults with severe
sepsis and septic shock (n= 1228), 28-day mortality was 37.5% compared with 44.1% [risk ratio (RR)
0.84, 95% confidence interval (CI) 0.72 to 0.97]. However, this finding contrasts with the results of the
largest completed trial (Corticosteroid Therapy of Septic Shock), which examined the role of low-dose
corticosteroids in patients with septic shock (n= 499); no significant difference in mortality was evident
between corticosteroid and placebo groups (34% vs. 31%).23 More recently, a large observational cohort
study reported higher overall mortality rates in patients with severe sepsis who received corticosteroids
than in those who did not (58% vs. 43%).24 The prevailing controversy regarding the role of low-dose
corticosteroids in severe sepsis is reflected in the inconsistent and varied use of corticosteroids observed in
clinical practice internationally, ranging from 9% to > 60% of patients enrolled in the Promoting Global
Research Excellence in Severe Sepsis registry in different countries.24 Currently, a further large randomised
controlled clinical trial of hydrocortisone in critically ill patients with septic shock is recruiting (target sample
size n= 3800); the intervention is hydrocortisone given as an infusion of 200mg/day for 7 days
(ClinicalTrials.gov identifier: NCT01448109).25
Potential harm of corticosteroids
A systematic review of corticosteroid trials in severe sepsis and septic shock did not identify any increased
risk of gastroduodenal bleeding, superinfection or neuromuscular weakness. An association with an
increased risk of hyperglycaemia (RR 1.16, 95% CI 1.07 to 1.25) and hypernatraemia (RR 1.61, 95% CI
1.26 to 2.06) was noted.
Of trials in community-acquired pneumonia, Meijvis et al.17 observed that hyperglycaemia was more
common in the treatment group, whereas Snijders et al.18 noted that the risk of hyperglycaemia requiring
additional therapy was non-significantly higher in the treatment group (2.3% of 104 vs. 0.9% of 109;
p= 0.27). Snijders et al.18 observed an increase in late failures in corticosteroid-treated patients compared
with control subjects, described as the need for an additional course of antibiotics, the need for another or
prolonged course of prednisolone or development of a parapneumonic effusion necessitating additional
therapy. Rebound inflammation as a result of the withdrawal of corticosteroids may explain this finding.
In contrast, Meijvis et al.17 did not observe any differences in late failure. This may relate to relative
differences between the half-lives of the different corticosteroids tested (prednisolone vs. dexamethasone).
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A meta-analysis of trials investigating the use of corticosteroids in acute bacterial meningitis observed that
participants who were treated with corticosteroids had an increase in recurrent fever (RR 1.27, 95% CI
1.09 to 1.47).26 The rate of persistent fever was lower in the corticosteroid-treated patients (RR 0.29,
95% CI 0.12 to 0.70), whereas other complications (including gastrointestinal haemorrhage) occurred in
similar proportions of treatment and control groups.
The Adjuvant Steroids in Adults with Pandemic influenza trial
The Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial is one of eight National Institute for
Health Research (NIHR)-funded pandemic studies set up in readiness for activation at the next pandemic;
it is the only randomised trial among the eight. To date, no randomised trials have been conducted
successfully during a pandemic. Key barriers to overcome include securing ethics and other regulatory
approvals in time, developing the necessary trial procedures and materials to use during a pandemic when
health services will already be overstretched, determining how best to offer consent to participants, staff
training, and doing all this in time for results to inform patient care within the same pandemic.
The aims of the ASAP trial are therefore to (1) determine whether or not low-dose corticosteroids given as
an adjunct to standard treatment is beneficial in patients hospitalised with severe pandemic influenza, and
(2) demonstrate that an ‘off-the-shelf’ model for a trial designed, set up and ready to activate during a
public health emergency is possible.
Methods
The trial study design and planned analyses are described below. Methodological aspects of trial set-up
and delivery that are unique to the ‘off-the-shelf’ nature of this study are reported below (see Results).
Study design
This is a pragmatic, blinded randomised placebo-controlled trial to determine whether or not during a
pandemic, a 5-day course of dexamethasone, started within 24 hours of admission, in addition to standard
care, is associated with a lower risk of death or admission to intensive care compared with placebo
for adults (≥ 16 years) admitted to hospital with an influenza-like illness. This trial will be conducted
at 30–40 sites across the UK during the first wave of the next influenza pandemic and will recruit
2200 participants, probably over a 6-week period.
The trial is set out in three phases: set-up, hibernation and activation. A summary of these phases is given
in Appendix 1 (see section 6.1, figure 1). During the hibernation phase, regular review of trial procedures
and sites will ensure that the trial is maintained in a state in which it can be rapidly activated to start
recruitment in the event of a pandemic. When the NIHR activates the trial, it will move to a preactivation
phase of 4–6 weeks. This final phase of trial set-up will include production and distribution of the trial
drug and trial materials, finalisation of trial procedures, and a check of site readiness prior to
beginning recruitment.
Participants
Adults with a clinical diagnosis of an influenza-like illness at the time of hospitalisation will be eligible for
recruitment to the ASAP trial; a laboratory diagnosis of influenza will not be required. The definition of an
influenza-like illness will be confirmed at the start of the pandemic and will conform to the definition
provided by Public Health England at the time.
Adults known to be taking or requiring corticosteroids at the time of hospitalisation, and those on
medication for the treatment of diabetes mellitus will not be eligible to participate in the trial.
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Participants will be randomised (1 : 1 ratio) to receive dexamethasone or placebo. An overview of the trial
design is given in Appendix 1 (see section 6.1, figure 2). Randomisation will be stratified by site. Each site
will receive batches of sealed trial treatment packs in a consecutively numbered series. The treatment
packs each contain (1) a 75-ml bottle of either dexamethasone 2mg/5ml or placebo (sufficient for 5 days
of treatment); (2) instructions for the take home pack (for participants discharged within 5 days of
admission); and (3) administration instructions. Trial treatment packs will be stored and available in
each area where patients with influenza will be admitted during a pandemic. The two treatments,
dexamethasone and placebo, are indistinguishable. Allocation to trial treatment will be by taking the next
in the series of treatment packs in that area. Participants will be considered to be in the trial once the trial
treatment pack label is completed regardless of whether or not they take any allocated treatment.
Intervention
The study intervention is dexamethasone administered as an oral liquid preparation, 6mg once daily for
5 days. Dexamethasone 6mg is equivalent to prednisolone 40mg or hydrocortisone 160mg.
Control
The study control is a matching placebo identical in colour, taste and consistency to the intervention.
In addition to the intervention/placebo, all patients will receive standard care for influenza, including
oxygen supplementation, fluids, antivirals and antibiotics as appropriate.
Materials
Dexsol® (dexamethasone) 2mg/5ml oral solution manufactured by Rosemont Pharmaceuticals Ltd
(PL 00427/0137) will be used in this trial.
A batch of matching placebo has been manufactured and is being stored by Rosemont Pharmaceuticals
Ltd. A new batch of placebo will be manufactured to replace outdated stock as appropriate.
Manufacturing time is approximately 4 weeks.
Three manufacturing units have been contracted to provide Investigational Medicinal Product (IMP)
packaging and release services.
Outcomes
The design and analysis of the trial includes the flexibility to allow for pandemics of different severity. In a
high-severity pandemic, the primary composite outcome is admission to intensive care or death by day 30.
Secondary outcomes are (1) length of stay in the ICU; (2) readmission to hospital within 30 days of hospital
discharge; (3) length of stay in hospital; (4) death within 30 days of admission to hospital; (5) admission to
ICU within 30 days of admission to hospital; and (6) general practitioner consultations within 30 days of
hospital discharge.
For the purposes of this trial, ‘admission to intensive care’ is defined as provision of level 3 care
(usually involving mechanical ventilation); this includes the provision of such care in non-traditional level
3 environments as might be encountered under contingency or crisis situations during a pandemic.27,28
This definition of ‘intensive care’ accords with the Department of Health planning assumptions.29 Most
patients who require critical care are likely to be mechanically ventilated at some point; during the
low-severity 2009 pandemic, 77% of patients managed in critical care in the UK required advanced
respiratory support.30
In a low-/moderate-severity pandemic, the primary outcome is time to hospital discharge, right censored at
30 days.
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At the outset of a pandemic, its severity will not necessarily be accurately appreciated. The ASAP trial is
planned in anticipation of a high-severity pandemic; this represents the most challenging situation for trial
execution and also the situation in which the trial results might have the largest public health impact. In
addition, at the start of a pandemic, patients with more severe illness will be more readily identified and
recognised compared with patients with mild or subclinical disease, hence potentially masking the true
overall nature of the pandemic. Uncertainty regarding the severity of a pandemic will remain until
sufficient data are gathered, which may not be until after the end of the first pandemic wave.
A review of pandemic severity will be conducted by the Trial Management Group and Trial Steering
Committee (TSC) as the pandemic unfolds. Decisions regarding the final analysis plan and final primary
outcome will rest with the TSC. These decisions are expected to be informed by discussions at the time
with the Department of Health, NIHR and Public Health England, and will be made before any analyses of
trial data are undertaken.
Current modelling estimates from the Department of Health are that for a high-severity pandemic, 35% of
those admitted to hospital will die and 25% will be admitted to intensive care. It is anticipated that if these
thresholds are not met, the pandemic will not be considered of ‘high severity’. For the purposes of the
ASAP trial, thresholds defining a low-severity epidemic compared with a moderate-severity pandemic are
less important.
Trial oversight
A TSC and a Data Monitoring Committee have been established. Yearly updates will be provided to these
committees during the hibernation phase.
Statistical considerations
For a high-severity pandemic, with 1100 participants in each arm, the trial will have > 90% power to
detect a 20% relative difference given a control event rate of 35%, or 80% power to detect a 15%
relative difference given a control event rate of 40%, both with 5% two-sided alpha level. Further details
of sample size estimates over a range of possible scenarios is given in Appendix 1 (see section 9.2).
For a low-/moderate-severity pandemic, a hazard ratio of 1.25, indicating an increased risk of discharge at
any given time, is considered as the minimum clinically relevant change to detect. With 90% power and
1% two-sided alpha level, 5% censored in the control arm, up to 10% die in hospital in both arms,
and 5% non-collection of primary outcome data, about 920 participants are required to be randomised
for a low-/moderate-severity pandemic.
The initial target total sample size for the ASAP trial is 2200 participants. If the pandemic is of low or
moderate severity, it is likely that fewer than 2200 participants will be randomised during the first wave of
approximately 6 weeks’ duration, although this definition will not be available until after the end of the
first wave. If more than 920 participants are randomised in a low-/moderate-severity pandemic then
smaller effect sizes may be detectable.
We will compare numbers, age and sex of randomised participants with aggregate summary data of all
patients who are admitted to hospital with influenza-like illness during the study period. We will compare
baseline characteristics of the randomised arms using appropriate descriptive statistics. Between-group
comparisons for primary and secondary outcomes will be conducted using an intention-to-treat (ITT)
approach, implemented using appropriate regression models, and with results presented as point
estimates, such as a ratio or difference comparing dexamethasone with placebo, with 95% CIs and
p-values.
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Secondary analyses will include additional adjustment for variables displaying an important imbalance at
baseline. We anticipate little, if any, missing primary outcome data and therefore will use ITT without
imputation as the main approach, and will investigate the influence of any missing data in sensitivity
analyses, including multiple imputation. All analyses will be conducted using Stata version 13 or higher
(StataCorp LP, College Station, TX, USA) or MLwiN 2.10 or higher (MLwiN, Centre for Multilevel
Modelling, Bristol, UK).
A planned early analysis focused on the primary end points will be performed to provide rapid data to the
UK Department of Health prior to the start of the second pandemic wave.
Preplanned subgroup analyses will be conducted for the primary outcome, based on the following baseline
factors: (1) duration of symptoms; (2) clinical diagnosis of pneumonia; (3) underlying comorbid illness;
and (4) severity of influenza. Outcomes will be reported descriptively by subgroup category and treatment
arm, and formally estimated by fitting interaction terms in the regression models. It is recognised that
power to detect subgroup effects is likely to be low, and these analyses will be regarded as exploratory
and interpreted with due caution.
Substudy
In parallel with the ASAP trial, we have set up a mechanistic substudy to be conducted at six pre-selected
trial-participating sites. The substudy will collect biological samples from 200 ASAP trial participants in
order to determine the interaction of steroid therapy and the host, and to apply this in interpreting the
clinical outcomes measured.
All patients recruited into the ASAP trial at substudy sites will be given the opportunity to participate in the
substudy. Consent for participation in the substudy will be taken separately to the ASAP trial. Two blood
samples and one nasal swab for subsequent transcriptomic and microbiological testing will be obtained
from participants at baseline and 48 hours post first dose of ASAP trial medication.
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Chapter 2 Results
This trial has not yet been activated. The status of the trial at the end of the set-up phase is reportedtogether with results from patient and public involvement (PPI) consultations.
Patient and public involvement regarding trial consent
Consultations with patients and the public regarding the ASAP trial, and specifically in relation to the consent
process, included events with representatives from charitable organisations related to respiratory disorders
(Asthma UK, British Lung Foundation, Cystic Fibrosis Trust, British Thoracic Society), PPI representatives of the
East Midlands Collaboration for Leadership in Applied Health Research and Care (CLAHRC), a local public
library reading group, and members of a town council. In addition, two independent front-line consultants –
who were, themselves, patients in the 2009 pandemic – were personally consulted. The majority view from
these consultations was a preference for a clear verbal consent process prior to trial enrolment in contrast to a
weightier written consent approach (Table 1). Initial opinions from a Research Ethics Committee (REC) also
favoured a verbal consent approach; indeed, REC approval for a verbal consent approach was given on
29 October 2013. This approval was subsequently reversed on 11 November 2013, on the grounds of existing
legal requirements in relation to controlled trials of investigational medicinal products [Clinical Trial of
Investigational Medicinal Product (CTIMPs)]. Following further extensive consultations involving the REC,
Health Research Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA) and NIHR,
during which the results of PPI consultations were made available, eventual REC approval was obtained on
19 February 2014, based on a written consent approach in accordance with current legislation.
Regulatory approvals
This trial has been approved by the UK MHRA (European Union Drug Regulating Authorities Clinical Trial
2013–001051–12) and the South Central – Oxford C REC (13/SC/0436). Global governance checks have
been completed in England, Wales and Scotland, enabling sites to issue local UK NHS permissions.
The study is International Standard Randomised Controlled Trial Number (ISRCTN) registered, and will be
conducted in accordance with the principles of the Declaration of Helsinki, the standards of Good Clinical
Practice (as defined by the International Conference on Harmonisation), and UK regulatory and
ethical requirements.
Owing to the lengthy hibernation period, MHRA approval was granted on the condition that a substantial
amendment is submitted at the time of activation to confirm that there is no change to the risk–benefit
analysis of the trial.
The requirement for an annual Development Safety Update Report (DSUR) was waived by the MHRA. In
place of this, an annual letter will be sent advising of any changes in risk–benefit analysis of the trial until
the trial is activated. Standard DSUR submissions will commence once the trial has been activated.
TABLE 1 Consent approaches preferred by persons (n= 44) consulted at PPI events
Consent approach No. of persons
Written consent 2
Verbal plus deferred written consent 0
Verbal consent 28a
Opt-out consent 15a
a One person felt that verbal consent and opt-out consent had equal merit.
DOI: 10.3310/hta19160 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 16
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Lim et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
7
NHS permissions
Twenty-nine sites have been granted NHS site permission and a further 11 sites are in the process of
obtaining local approvals (data as of 22 January 2015). These sites cover a wide geographical area across
the UK, including most major cities (Figure 1).
FIGURE 1 Participating sites in the UK (as of 22 January 2015).
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The ASAP trial, together with other studies identified as urgent public health research, have been excluded
from the NIHR Clinical Research Network (CRN) high-level objective of ‘first patient, first visit within
70 days’, thus enabling sites to grant NHS permission in advance of trial activation.
Trial activation
The trial will be activated at the request of NIHR. The decision to activate will be informed by close
discussions with Public Health England, trial investigators and the TSC. Recruitment will occur at influenza
admission points in all participating sites. It is anticipated that recruitment will be completed by the end of
the first wave of the pandemic.
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Chapter 3 Discussion
To our knowledge, this is the first multicentre clinical trial that has been set up in order to be placed inhibernation, ready for rapid activation at an unspecified future date. The biggest challenge in setting
up this trial has been the uncertainty regarding the timing and severity of a future influenza pandemic.
Being prepared for pandemics of different severities was one of the major learning points from research
conducted during the 2009 pandemic.31
The trial design is based on the event of a high-severity pandemic, this being the default position at the
start of a pandemic when the severity of a pandemic may not yet be apparent. To allow for a less severe
pandemic, we have included flexibility within the trial conduct and analysis.
Choice of intervention
Different corticosteroids have been, and are currently being, tested in the context of acute severe
infections and sepsis. The most commonly used oral preparations are dexamethasone and prednisolone.
Compared with prednisolone, dexamethasone has (1) minimal mineralocorticoid activity and does
not affect sodium and water balance, thus avoiding potential problems with fluid retention, which are not
uncommon in severe viral pneumonitis, and (2) a comparatively long biological half-life, potentially offering
protection against late failures resulting from rebound inflammation.17
The oral liquid preparation will enable the vast majority of eligible participants to receive the intervention
except those who are either strictly ‘nil by mouth’ or who are unable to swallow. For some of these
participants, administration via an enteral feeding tube will be possible. This approach is similar to the
manner in which oseltamivir (Tamiflu®, Roche) was administrated during the 2009 pandemic [no
intravenous (i.v.) formulation licensed at the time], when only a small proportion (< 3%) of patients in
intensive care received ‘off-licence’ i.v. antiviral therapy.32
The oral absorption of corticosteroids in patients who are admitted to hospital with severe respiratory
illness or sepsis might potentially be impaired as a result of delayed gastric emptying or altered first-pass
metabolism.33 In an open-label randomised trial of i.v. dexamethasone compared with oral dexamethasone
in patients who were admitted to hospital with community-acquired pneumonia, oral bioavailability was
found to be good (81%) and comparable with results from studies performed in healthy individuals.34
No equivalent studies have been performed in critically ill patients and it remains possible that the very
sickest patients will experience impaired oral absorption of dexamethasone. These patients are likely to be
managed on an ICU (meeting one of the primary end points) and to represent a small proportion of the
study cohort. Overall, the potential benefit of providing an i.v. preparation, with matching placebo, for use
in selected trial participants, was considered to be outweighed by the risks this would pose to the practical
and successful conduct of the trial in the context of a pandemic.
Evidence from existing trials of low-dose corticosteroids have not identified an increased risk of
gastrointestinal complications, therefore no additional requirement for gastroprotection is required in this
trial. The coherence of these decisions in relation to the trial intervention will continue to be reviewed
during the hibernation phase of the trial as results from ongoing studies become available.25,35
The following discussion highlights the hurdles encountered in setting up this trial and the considered
threats to the successful conduct of this trial during a pandemic. Other investigators planning to set up
similar ‘off-the-shelf’ clinical trials in response to public health crises may encounter similar challenges.
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Hurdles
Pressure on NHS resources
In the event of a high-severity pandemic, the NHS will be under considerable pressure to continue to
deliver high-quality care to all patients. Under such circumstances, any additional non-essential work is
likely to be deferred. This applies at the individual level as well.
The successful conduct of pragmatic acute care multicentre trials is challenging at the best of times.
The need for any research-specific measurements requiring additional patient involvement or follow-up
increases trial complexity and hence the burden of research, with potentially negative impacts on trial
conduct. These challenges are magnified during a pandemic.36 To reduce any extra work related to
participation in the ASAP trial, trial processes and procedures were minimised to the bare essentials.
No additional investigations or measurements are necessary for the ASAP trial; data required for all major
outcome measures will be captured from routine medical data sources.37
Co-enrolment of patients
At the time of reporting, there were at least four pandemic studies that were planning to recruit patients
with influenza infection in the UK hospital setting: two are part of the NIHR pandemic portfolio. Of these
four studies, the only clinical intervention trial is the ASAP trial; the others are observational cohort or
biological sampling studies.
The chief investigators of these trials have agreed that there is no bar to co-enrolment of patients to the
ASAP trial and another study. However, other pandemic studies may be set up in future, which may
compete for the same patient pool. Even if a principle of co-enrolment could be observed, it may not be
acceptable for patients to be approached to participate in multiple studies simultaneously.
An expansion of pandemic studies in future will likely require some degree of prioritisation of the delivery
of such research. For instance, although patients entered into the ASAP trial will not be eligible to
participate into another trial simultaneously, if a patient is admitted to intensive care and hence meets one
of the primary composite end points for a high-severity pandemic, it may be reasonable to consider trial
exit for that patient and subsequent enrolment in another trial. Such a decision would depend on a
number of factors, including whether or not the severity of the pandemic had already been definitively
declared, as this would affect the primary end point for the ASAP trial, the potential public health impact
of different trials, the likelihood of completion of a trial, possible biological interactions and patient wishes.
Whether such prioritisation should be left to local sites or co-ordinated more centrally warrants exploration
as part of pandemic preparedness planning.38 The NIHR has established a CRN Urgent Public Health Group
to help ensure that urgent public health studies can be set up and delivered quickly and effectively.39
Commercial studies may apply for approval as relevant to the urgent public health risk. However,
co-enrolment involving commercial studies, whether observational or interventional, may not meet with
approval by industrial partners. The impact of allowing or disallowing co-enrolment should be carefully
considered at the time of approval of studies for priority status within the CRN urgent public health
research framework.
Engagement of sites
Maintaining the interest and focus of sites through the set-up process has required constant effort.
Understandably, because of the perception that the ASAP trial may not be activated for an undefined
period of years, there is less impetus to work on this trial compared with that of other trials that have
more imminent datelines.
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Establishing dialogue with a core team of local investigators at each site, and enabling them to better
anticipate the potential barriers to conducting a trial during a pandemic, has coincided with the role of
‘pandemic champions’ promoted by the Infectious Diseases and Microbiology Specialty Group to the
NIHR CRNs.
The support of the Specialty Group has been invaluable not only for establishing links with interested sites,
but also in raising national awareness of the trial. To ensure the delivery of pandemic research, the
Specialty Group has prepared a suite of documents around urgent public health research and how it will
support delivery. The ASAP trial is a recognised urgent public health study; this has provided valuable
reassurance to sites of their ability to conduct clinical research during such an emergency.
Site visits during the hibernation phase may be required to maintain study awareness and confirm
pandemic preparedness. Including the delivery of NIHR-funded pandemic studies in individual NHS trust
pandemic plans is a further desirable step towards integrating pandemic research into service delivery.
Site selection
Although it is anticipated that any future influenza pandemic would affect the whole of the UK, different
regions may be more or less severely affected. The location and distribution of pandemic ‘hot spots’
is unpredictable.1
The 40 sites participating in the ASAP trial are well distributed across the UK. Sites that do not experience
much influenza activity during the first pandemic wave may not be activated. In addition, we have provided
for a ‘flying squad’ of research nurses to respond to ‘hot spots’, in support of local research teams.
The occurrence of ‘hot spots’ increases the probability of patient transfers from one hospital to another to
maintain patient flow and bed capacity. It is not possible to predict which hospitals might be involved in
receiving patients. We are currently working on a generic site-specific information form for continuing care
sites, to enable non-recruiting sites to continue IMP administration and data collection should a trial
participant be transferred in.
Supply of Investigational Medicinal Product
A high-severity pandemic would not only place the NHS under considerable pressure, but also would affect
other businesses, particularly through staff sickness. To improve resilience in the supply of IMP and placebo to
participating trial sites, contracts with multiple manufacturing and distribution units have been established.
Training of local investigators
Local health-care workers (HCWs) will need to be actively involved in the identification of patients who
are eligible for the ASAP trial and taking patient consent. Informing and training large numbers of local
HCWs with regards to the ASAP trial in advance of a pandemic (i.e. in the interpandemic period) is
unsustainable. More junior HCWs, in particular, will be likely to move on before the trial is activated and
the remaining HCWs would require refresher training prior to trial activation.
A suite of trial-specific training material has been prepared jointly with Good Clinical Practice trainers, in
consultation with the NIHR. This material has been designed to be easy to read and suitable for rapid
dissemination in the preactivation phase to local HCWs who will be involved in the trial.
Command and control
During the severe acute respiratory syndrome outbreak in 2003, good command and control was
identified as a major factor in the management of patients and hospital resources.40 At the same time,
undue reliance on any single individual or process is to be avoided.
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The Nottingham Clinical Trials Unit (NCTU) has begun development of an internal pandemic plan to
increase its resilience in the event of a pandemic, with special emphasis on the successful delivery of the
ASAP trial. This includes the potential move of the trial team to an off-hospital site, away from clinical
areas where patients with influenza will be managed. Online resources are being developed, both as a
repository of information and a means for rapid updates to participating sites.
Threats
Changes during hibernation
The timing of a future pandemic is unpredictable. The ASAP trial has been set up with a hibernation phase
of up to 10 years. There will inevitably be local and national infrastructural, policy and staff changes in this
time. Maintaining trial readiness throughout these changes will require active management. As an
example, in anticipation of a move overseas to take up a research directorship post, one of the trial
co-investigators (SG) has already engaged another investigator (D Wootton) to take over responsibilities
related to the ASAP trial. Such future-proofing strategies require forethought and long-term commitment.
Unforeseen changes that might undermine the integrity of the trial as it is currently set up may yet arise.
Advances in the management of severe acute respiratory illnesses and the potential introduction of new
therapies for severe influenza in particular may prompt alterations to the trial during the hibernation
phase. An adaptive trial design to enable other treatment arms to be added to the ASAP trial is one
consideration; any additional resources required may be justified in view of potential gains.
Lack of research staff
Current planning assumptions are that up to 50% of staff may be affected over the period of the
pandemic, either directly by the illness or by caring responsibilities, thereby creating potential pressures on
the response.41 In addition to absenteeism, research staff may also be diverted to front-line clinical work.
Lack of staff was identified as the main reason for poor recruitment in a pandemic trial that had to be
terminated prior to completion during the 2009 pandemic.42 To mitigate against this, we have designed
the study to minimise the research sources required from sites for the conduct of this study; for instance,
data collection and the Case Report Form have been designed with completion by trained administrative
staff, and not necessarily by research nurses, in mind. Nevertheless, a minimum core team of local research
investigators will be required at each participating site.
Employment of new research staff to support the conduct of the ASAP trial is unlikely to be feasible in
view of the short time scale from recognition of a pandemic to trial activation. Redeployment of research
staff from other areas of research will be required. The Comprehensive Local Research Network (CLRN)
have prioritised the NIHR pandemic portfolio of studies. However, no standing agreement is in place
between NIHR and other funding bodies, such as the Medical Research Council or Wellcome Trust.
High-level cross-organisational agreement is needed. Discussions held during the interpandemic period to
agree on principles for prioritisation will help facilitate the more detailed discussions that will be required at
the onset of a pandemic. Ultimately, the successful delivery of this trial will depend crucially on the timely
and sufficient support by CLRN units at all participating sites during the pandemic.
Written informed consent
The process of taking written informed consent for a research study can potentially lead to delays in
patient care with clinical consequences. This is most likely to occur when research is conducted in the
context of emergency care.43 Some patients with severe influenza will present to hospital in a state of
emergency; the mean time from hospital admission to ICU transfer was 2 days during the 2009
pandemic.2 In addition to individuals who require emergency care, a state of emergency will also prevail
across the management of all patients because of the pressures on the NHS, particularly in the context of a
high-severity pandemic.
DISCUSSION
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The current legal requirement for a CTIMP, such as the ASAP trial, is for written informed consent, outside
the waiver for emergency research.44 This waiver applies only to individuals who require emergency care
and does not include situations when the health service is in a state of emergency.
The consent approach for the ASAP trial (written informed consent) adheres to existing legal and regulatory
standards for a CTIMP. However, as identified during PPI consultations, this may place it at odds with the
opinions of patients and the public during a pandemic. Whether or not this will adversely impact on
recruitment rates or patient management remains to be determined.
Public engagement: social media
The public’s perception of pandemics is variable.45,46 Experience of the 2009 pandemic, which was less
severe than initially portrayed, may alter how news regarding a future pandemic is received. The ASAP trial
might receive wide media exposure during a pandemic and the tone of such media coverage could impact
on the conduct of the trial. A public relations strategy for the NIHR pandemic portfolio of studies, including
the ASAP trial, will be necessary from the time of activation.
A model for ‘off-the-shelf’ trials in public health emergencies
An influenza pandemic constitutes a public health emergency, as do bioterrorist attacks, natural disasters
(such as severe flooding) and major industrial accidents leading to toxic exposures, such as from the
Fukushima nuclear reactor in Japan. Awareness of the need to be better prepared to resolve important
research questions in the context of a public health emergency has been growing over the last decade.47
Randomised trials provide the best evidence to guide clinical practice and health policy. However, public
health emergencies are, by nature, unpredictable in their timing and scale. In addition, they are typically of
limited duration. These aspects pose considerable challenges to the design, set-up and execution of
randomised trials.
Lessons learnt from the set-up of this study may benefit the design of other ‘off-the-shelf’ trials in future.
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Chapter 4 Conclusion
Advance set-up of a pandemic trial with full regulatory approvals in place enables the resolution ofmany issues at an early stage outside the ‘heat’ of a pandemic. Regular attention to trial readiness
during the hibernation phase will be required. This study serves as a model for the development of other
‘off-the-shelf’ trials as part of preparedness planning for public health emergencies.
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1 AMENDMENT HISTORY 
 
Amendment 
No. 
Protocol 
Version 
No. 
Date 
issued 
Author(s) of 
changes 
Details of Changes made 
Protocol 
amendment 1  
(Amendment 
ref. SA02) 
1.0 23-Oct-13 Dr Wei Shen Lim Update to consent section; 
replacement of initial verbal 
consent with use of a single page 
combined patient information 
sheet and consent form at the 
point of hospital admission.  
Protocol 
Amendment 2 
(Amendment 
ref: SA08) 
2.0 11-Feb-14 Dr Wei Shen Lim 
 
Addition of Appendix B 
(mechanistic sub-study) 
 
Correction made to section 6.3.3 
that trial treatment will be 
discontinued if participant is later 
found to meet exclusion criteria. 
 
Added that an appropriately 
trained research nurse may take 
written consent. 
 
Added that treatment pack will 
also contain a spoon for drug 
administration and a wristband for 
trial participants 
 
Minor spelling 
corrections/administrative 
changes. 
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2 SYNOPSIS 
Study Title Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo-controlled trial 
Internal ref. no. 11RM013 
Clinical Phase  Phase III 
Trial Design Pragmatic multi-centre double-blind randomised trial 
Trial Participants Adults (≥ 16 years old) hospitalised with an influenza-like illness during a pandemic. 
Planned Sample Size 
2200 patients. 
The planned sample size is based on the range of possible scenarios that 
might be encountered during a pandemic. With 2200 patients, the study will 
have 90% power to detect a 15% relative reduction in the primary outcome 
(admission to intensive care or death). 
Follow-up duration 
Patients will be asked to complete a follow-up questionnaire 30 days after 
hospital discharge. Completion of the questionnaire is not required for patients 
hospitalised ≥60 days. Patient outcome information will be collected from 
hospital-based system records for these patients. 
Planned Trial Period 
The trial is unique as it will be set up pre-pandemic. Once set-up is complete 
and all the required approvals have been obtained, the trial will be placed into 
‘hibernation’. 
 
After the initial set-up, there will be 3 distinct phases to the trial. 
 
1) Hibernation phase 
During hibernation, regular review (at least annually) of trial procedures and 
sites will ensure that the trial is maintained in a state in which it can be readily 
activated to start recruitment in the event of a pandemic. 
 
2) Pre-activation phase 
When the National Institute for Health Research (NIHR) decide to activate the 
trial, a pre-activation phase of four to six weeks will begin immediately. This will 
include final review of trial procedures, trial drug production and distribution, 
production and distribution of trial materials and a check of site readiness prior 
to beginning recruitment. 
 
3) Activation phase 
During activation, patients will be recruited into the trial. Recruitment Is 
planned to be completed within the first pandemic wave, typically of six weeks 
duration. This phase also includes data collection and follow-up. 
 
Primary Objective 
To determine whether during a pandemic, for adults (≥16 years) hospitalised 
with an influenza-like illness, a 5-day course of dexamethasone started within 
24 hours of admission to hospital, in addition to standard care, is associated 
with a lower risk of death or admission to intensive care compared to placebo. 
 
Secondary Objectives 
To determine whether dexamethasone given in addition to standard care is 
associated with a reduction in the length of hospital stay, the frequency of 
hospital readmission and/or the frequency of GP consultations after discharge 
compared to placebo. If dexamethasone is effective, the study will also 
evaluate its cost-effectiveness. 
 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
 ASAP Trial Protocol Final Version 3.0 dated 07-Oct-2014  Page 9 of 40 
Primary Endpoint Admission to intensive care unit or death, within 30 days of hospital admission 
Secondary Endpoints 
1. Length of stay in intensive care unit 
2. Readmission within 30 days of hospital discharge 
3. GP consultations  within 30 days of hospital discharge 
4. Length of stay in hospital 
5. Death within 30 days of admission to hospital 
6. Admission to intensive care unit within 30 days of admission to hospital 
 
The full statistical analysis plan for this trial includes the flexibility to allow for 
pandemics of different severity. 
Investigational 
Medicinal Product 
Dexamethasone, given as adjuvant therapy in addition to standard care.  
Form: Liquid 
Dose: 6 mg once daily for 5 days from randomisation 
Route: Oral (or enteral through nasogastric tube) 
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3 ABBREVIATIONS 
 
AE Adverse event 
ASAP Adjuvant Steroids in Adults with Pandemic Influenza 
CI Chief Investigator 
COPD  Chronic Obstructive Pulmonary Disease 
CFR Case Fatality Ratio 
CRF  Case Report Form 
DMC  Data Monitoring Committee 
GCP Good Clinical Practice 
GP General Practitioner 
ICH International Conference of Harmonisation 
ICU Intensive Care Unit 
IMP Investigational Medicinal Product 
ITT Intention-to-treat 
LOS Length of stay in hospital 
MHRA Medicines and Healthcare products Regulatory Agency 
NCTU Nottingham Clinical Trials Unit 
NETSCC NIHR Evaluation, Trials and Studies Coordinating Centre 
NHS National Health Service 
NIHR National Institute for Health Research 
PHE Public Health England 
R&D NHS Trust R&D Department 
REC Research Ethics Committee 
SAE Serious Adverse Event 
SAR Serious Adverse Reaction 
SOP Standard Operating Procedure 
SPC Summary of Product Characteristics 
SUSAR Suspected Unexpected Serious Adverse Reactions 
TMG Trial Management Group 
TSC Trial Steering Committee 
WHO World Health Organisation 
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4 BACKGROUND AND RATIONALE 
 
Pandemic influenza occurs when a new influenza A virus strain emerges which is antigenically distinct 
from circulating influenza strains, and which is able to infect humans, spreading efficiently from person to 
person causing significant clinical illness in a high proportion of those infected. Since the beginning of the 
20th century, there have been 4 influenza pandemics of varying severity. The devastating 1918 pandemic 
(‘Spanish flu’) caused by influenza A/H1N1 resulted in 20 to 50 million deaths worldwide, representing a 
case-fatality ratio (CFR) of 2 – 3%. Subsequent pandemics in 1957 (H2N2) and 1968 (H3N2) resulted in 
approximately 1 to 4 million deaths worldwide; CFR 0.1 to 0.4%. In contrast, the 2009 pandemic (H1N1) 
was much less severe. It affected mainly people aged below 55 years of age, and had a low case-fatality 
ratio (0.025%) in the UK similar to that of recent seasonal influenza viruses [1]. The timing and severity of 
future influenza pandemics remains unpredictable. There are currently no markers that will predict the 
pathogenicity or spread of a potential pandemic strain in the human population. Therefore, any plans for a 
future pandemic need to be flexible and take account of different possible scenarios from mild to severe. 
 
Presentation and prognosis   
Influenza virus infection is associated with a wide spectrum of illness, from no symptoms to pneumonia 
and death.  During a pandemic, most people are expected to experience a minor influenza-like illness 
characterized by fever and cough typically lasting 7 to 10 days. Nevertheless, the UK Pandemic Influenza 
Preparedness Strategy 2011 recommends that for pandemic planning an estimated 1-4% of symptomatic 
patients should be expected to require hospital care.[2] Patients may be admitted to hospital either 
because of influenza-related exacerbations of underlying co-existing illnesses such as chronic obstructive 
pulmonary disease (COPD), or due to  complications of influenza infection such as pneumonia.   
 
Following hospital admission, some patients deteriorate rapidly (within 24 hours) and require intensive 
care unit (ICU) level support for respiratory failure. The proportion who might require ICU support in a 
pandemic is difficult to predict, and a range of 15% to 25% of hospitalized patients has been suggested. In 
a severe pandemic, resource limitations will probably define the upper limit. In the 2009 H1N1 pandemic 
(a low severity pandemic), 17% of hospitalized patients were admitted to Level 2 or Level 3 care;[3] the 
median time from symptom onset to ICU admission was 6 days, and from hospital admission to ICU 
admission was 2 days. 
 
A figure of up to 200,000 additional deaths across the UK over a 15 week period has been proposed for 
planning purposes in the UK Pandemic Influenza Preparedness Strategy 2011. In the ‘low severity’ 2009 
pandemic, 7% of hospitalized patients with confirmed H1N1 influenza infection died [3] . 
 
Current standard therapy for influenza infection 
In the management of patients admitted to hospital with influenza infection during a pandemic, current 
Clinical Management Guidelines recommend that all adults receive appropriate supportive care, including 
fluid replacement and oxygen supplementation, and antiviral therapy [4].  In addition, antibiotic therapy is 
recommended for all hospitalised adults except previously well adults with only influenza-related acute 
bronchitis.  
 
Corticosteroids in influenza  
During the early phase of illness, influenza A virus infection induces inflammatory (e.g. IL-6, IL-8) and T-
helper type 1 (Th1) cell immune responses (e.g. IFN-induced protein 10 (IP-10), monokine induced by 
IFN-gamma (MIG), correlating with clinical illness [5]. Hypercytokinaemia is also recognized in patients 
with H5N1 influenza infection (e.g. IL-6,IL-10, MIG) with the highest levels found in patients who 
subsequently die [6]. Similar changes have been observed in patients with 2009 pandemic H1N1 infection 
[7]. Such inflammatory cytokines may suppress the hypothalamic-pituitary-adrenal axis resulting in relative 
adrenal insufficiency or compete with intracellular glucocorticoid receptor function, resulting in peripheral 
tissue steroid resistance [8]. Corticosteroids in low doses (e.g. hydrocortisone ≤ 300mg per day or 
dexamethasone ≤ 11.25 mg/day) downregulates proinflammatory cytokine transcription and has been 
shown to improve innate immunity in patients with septic shock [9, 10].  
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There are no completed randomised trials of the use of corticosteroids in patients with pandemic, avian or 
seasonal influenza infection. Corticosteroid use in influenza is widespread, non-systematic and marked by 
controversy [11-14].  During the 2009 pandemic, corticosteroid use in critically ill patients with H1N1 
influenza was identified in 83 (30%) of 208 patients in a French registry [15], 107 (44%) of 245 patients in 
a South Korean cohort study and 126 (57%) of 220 patients in the European Society of Intensive Care 
Medicine H1N1 registry [16]. The heterogeneity of these cohort studies and non-randomised study 
designs preclude any firm conclusions regarding the risks or benefits of corticosteroids in influenza. In 
these cohort studies of critically ill patients with 2009 H1N1 pandemic influenza, the association of 
corticosteroids with mortality varied from a decrease in mortality, to no effect on mortality or an increase in 
mortality [13, 15-17]. Some cohort studies observed an association of corticosteroids with an increase in 
hospital acquired pneumonia, including fungal pneumonia [13, 15-17]. One cohort study of 83 hospitalised 
patients, of whom 17 received parenteral corticosteroids during the first 72 hours of illness, observed an 
increased risk of critical illness in corticosteroid treated patients (RR 1.8,  95% CI 1.2 to 2.8) [18]. Although 
multivariate analyses were employed in most of these studies, bias arising from confounding by indication 
(corticosteroids prescribed in the sickest patients as a 'treatment of last resort') cannot be fully discounted. 
The World Health Organisation (WHO) Clinical management of human infection with pandemic (H1N1) 
2009 : revised guidance[19] recommended that systemic corticosteroids should not be given in severe 
influenza unless indicated for other reasons or as part of an approved research protocol. A Cochrane 
meta-analysis of studies of corticosteroids in influenza is on-going and will inform the yearly review of the 
Trial Protocol during the hibernation phase. 
 
A) Effectiveness of corticosteroids in pneumonia. Trials of corticosteroids in patients hospitalised with 
community acquired pneumonia have reported varying results.  Meijvis et al (n=304) observed a 
significant reduction in median length of stay together with greater declines in C-reactive protein (CRP) 
and interleukin-6 levels in the treatment arm (dexamethasone 5 mg for 4 days) [20]. In contrast, Snijders 
et al (n=213) did not detect a significant difference in clinical cure rate at Day 7 despite a faster rate of 
defervescence and decline in CRP levels in the treatment arm (prednisolone 40 mg for 7 days) [21]. An 
earlier small, inadequately powered, open-labelled trial by Mikami et al (n=31), did not detect any 
statistical difference in length of stay between groups [22]. 
 
In patients with severe community acquired pneumonia admitted to intensive care (ICU) [23], Confalonieri 
et al found hydrocortisone was significantly associated with improved oxygenation and a reduction in 
multiple organ dysfunction score on Day 8, and a reduction in delayed septic shock. This trial was stopped 
early (n=46) per protocol after the upper stopping boundary for improvement in oxygenation (PaO2/FiO2 
ratio) was achieved. A significant reduction in length of stay (13 v 21 days, p = 0.03) and mortality (0% v 
30%, p=0.009) was also observed.  
 
B) Effectiveness of corticosteroids in sepsis. A systematic review of trials examining the benefit of 
corticosteroids in severe sepsis and septic shock in adults identified [24] 12 randomized or quasi 
randomised trials (n=1228) comparing low dose corticosteroids (hydrocortisone ≤ 300mg per day 
(equivalent to dexamethasone 11.25 ≤ mg/day)) for ≥ 5 days with placebo or supportive care. The 28-day 
mortality for treated versus control patients was 37.5% versus 44.1% (RR 0.84, 95% CI 0.72 to 0.97). 
These results included the study by Confalonieri et al, 2005.  Similar results were observed when this trial 
was removed from the analysis (RR 0.87, 95% CI 0.77 to 0.98). These studies of corticosteroids in sepsis 
differ from the studies in community acquired pneumonia in the timing of corticosteroid intervention; 
occurring later in the disease process when severe sepsis or septic shock was evident.  
 
Potential harm of corticosteroids 
A systematic review of corticosteroid trials in severe sepsis and septic shock did not identify any increased 
risk of gastroduodenal bleeding, superinfection or neuromuscular weakness. An association with an 
increased risk of hyperglycaemia (RR 1.16, 95% CI 1.07 to 1.25) and hypernatraemia (RR 1.61, 95% CI 
1.26 to 2.06) was noted.  
 
Of  trials in community acquired pneumonia, Meijvis et al observed that hyperglycaemia was commoner in 
the treatment group, while Snijders et al noted that the risk of hyperglycaemia requiring additional therapy 
was non-significantly higher in the treatment group (2.3% of 104 v 0.9% of 109, p=0.27) [20, 21].  Snijders 
et al observed an increase in late failures in corticosteroid treated patients compared to controls; 
described as the need for an additional course of antibiotics, need for another or prolonged course of 
prednisolone or development of a parapneumonic effusion necessitating additional therapy. Rebound 
inflammation due to the withdrawal of corticosteroids may explain this finding. In contrast, Meijvis et al, did 
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not observe any differences in late failure. This may relate to relative differences between the half-lives of 
the different corticosteroids tested (prednisolone vs dexamethasone).   
 
A meta-analysis of trials investigating the use of corticosteroids in acute bacterial meningitis observed that 
participants treated with corticosteroids had an increase in recurrent fever (RR 1.27, 95% CI 1.09 to 1.47) 
[25]. The rate of persistent fever was lower in the corticosteroids treated patients (RR 0.29, 95% CI 0.12 to 
0.70) while other complications (including gastrointestinal haemorrhage) occurred in similar proportions of 
treatment and control groups. 
 
Choice of trial intervention 
Dexamethasone, compared to prednisolone, has a) minimal mineralocorticoid activity and does not affect 
sodium and water balance, thus avoiding potential problems with fluid retention which are not uncommon 
in severe viral pneumonitis, and b) a comparatively long biological half-life of 36 to 54 hours; thus 
extending the pharmacological effects of a 5 day treatment course to over 11 days and potentially offering 
protection against late failures due to rebound inflammation. 
 
Description of study intervention 
The study intervention is dexamethasone administered as an oral liquid preparation, within 24 hours of 
hospital admission. The regimen is 6 mg once daily for five days. Dexamethasone 6 mg is equivalent to 
prednisolone 40 mg or hydrocortisone 160 mg. 
 
The oral liquid preparation will enable the vast majority of eligible participants to receive the intervention 
except those who are either strictly ‘nil by mouth’ or are unable to swallow. For some of these participants, 
administration via an enteral feeding tube will be possible. This approach is similar to the manner in which 
oseltamivir (no IV formulation licensed at the time) was administrated during the 2009 pandemic, when 
only a small proportion (less than 3%([26], [27])) of patients in intensive care received ‘off-licence’ 
intravenous antiviral therapy.  
5 OBJECTIVES 
5.1 Primary Objective 
To determine whether during a pandemic, for adults (≥16 years) hospitalised with an influenza-like illness,  
a 5-day course of dexamethasone started within 24 hours of admission to hospital, in addition to standard 
care, is associated with a lower risk of death or admission to intensive care compared to placebo. 
5.2 Secondary Objectives 
To determine whether dexamethasone given in addition to standard care is associated with a reduction in 
the length of hospital stay, the frequency of hospital readmission and/or the frequency of GP consultations 
after discharge compared to placebo. If dexamethasone is effective, the study will also evaluate its cost-
effectiveness.  
 
6 TRIAL DESIGN 
6.1 Summary of Trial Design 
The ASAP trial is a pragmatic multi-centre double-blind randomised placebo-controlled trial.  The 
trial design is based on the event of a high-severity pandemic; this being the default position at the start of 
a pandemic when the severity of a pandemic may not yet be apparent. 
 
The trial will be set-up pre-pandemic. Once set-up is complete and the required approvals have been 
obtained, the trial will be placed into ‘hibernation’. It will be activated during an influenza pandemic only if 
instructed by the National Institute for Health Research (NIHR). During the hibernation phase, regular 
review (at least annually) of trial procedures and sites will ensure that the trial is maintained in a state in 
which it can be rapidly activated to start recruitment in the event of a pandemic. If the NIHR activate the 
trial it will move to a pre-activation phase of 4-6 weeks. This final phase of trial set-up will include 
production and distribution of the trial drug and trial materials, finalisation of trial procedures, and a check 
of site readiness prior to beginning recruitment. A summary of the trial phases is shown in Figure 1. 
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ACTIVATION (approx. 6 weeks) 
Recruitment of trial participants 
PRE-ACTIVATION (4-6 weeks) 
Finalisation of trial procedures, activation  of IMP manufacture, 
final check of trial sites 
HIBERNATION 
Trial maintained in 'ready to go' state with regular review of trial 
procedures and trial sites
SET-UP 
Sites selected, approvals gained, processes established. 
 
 
Figure 1: Phases of ASAP trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on a high-severity pandemic the trial will recruit 2200 patients, and flexibility has been included in 
the design of this trial to allow for pandemics of lower severity. Detailed information can be found in the 
Statistical Analysis Plan. The final sample size will be determined in conjunction with the Trial Steering 
Committee during the activation phase of the trial, once information about the severity of the pandemic is 
available. It is anticipated that there will be up to 50 centres participating in the UK, covering a wide 
geographical spread. 
 
Adults (≥16 years) admitted to hospital with an influenza-like illness will be screened for entry into the trial 
within 24 hours of admission to hospital. Once consent for trial participation has been obtained, eligible 
patients will be randomised into the trial. Participants will be allocated to receive either dexamethasone or 
placebo. Both will be given as a liquid (orally or via a nasogastric feeding tube) once a day for 5 days 
whilst the participant is in hospital, or continued at home if the participant is discharged within 5 days of 
admission to hospital. All other clinical care will be according to national clinical management guidelines 
for pandemic influenza.  
 
Routinely available data recorded in hospital records at the time of hospital admission will be collected 
once consent for trial participation has been obtained. Data on outcome will be collected from hospital 
FLU PANDEMIC DECLARED 
DECISION MADE TO ACTIVATE TRIAL  
(TRIAL SITES NOTIFIED) 
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records upon discharge from hospital, or on Day 30 whichever is sooner (Day 1 = day of admission to 
hospital). 
 
Participants will be sent a postal follow-up questionnaire to complete 30 days after hospital discharge.  
This will ask whether they have consulted their GP or been readmitted to hospital since being discharged 
from hospital. In addition, for those who were discharged within 5 days of admission and given their trial 
treatment to take home, information about treatment compliance will be requested. Participants who do 
not return this follow-up questionnaire within seven days of the expected completion date will be contacted 
by telephone by a member of the Nottingham Clinical Trials Unit (NCTU) to request the information. If a 
participant remains hospitalised at Day 60, completion of the follow-up questionnaire is not required. 
Patient outcome data for these patients will be collected from hospital-based system records.  
 
Participants do not have any additional study visits. 
 
Participants are considered to be in the trial once the trial treatment pack label has been completed 
(randomisation) until the follow-up questionnaire has been received by the NCTU (or, when a participant, 
who fails to return the questionnaire, provides the answers over the telephone instead). For any 
participants that die, inclusion in the trial will be from randomisation until the date of the participant’s 
death. The participant will be considered lost to follow-up if the questionnaire is not returned and the 
NCTU are unable to contact the participant by telephone.  
 
Please see Figure 2 for an overview of the trial design. 
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Figure 2: Overview of trial design 
 
  
Admission to hospital with influenza-
like illness during pandemic & meets 
eligibility criteria 
Obtain consent at admission 
Randomise 
(Day 1) 
Allocated to dexamethasone 6mg 
once daily for 5 days 
(Day 1-5) 
Allocated to placebo once daily for 5 
days 
(Day 1-5) 
*Data collected at discharge or Day 30 if the patient remains hospitalised, whichever is sooner. In event of death data will also be collected. 
** For patients hospitalised ≥60 days, no follow-up questionnaire is required; patient outcome data will be collected from hospital-based systems 
Completion of postal questionnaire**  
Date of discharge + 30 days 
OBTAIN WRITTEN CONSENT FOR 
PARTICIPANTS THAT LACKED 
CAPACITY AT ADMISSION 
Collection of admission data from hospital 
records 
(Day 1) 
Collection of outcome data from hospital 
notes and health care information systems 
(Upon discharge or Day 30*) 
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6.2 Outcome measures 
6.2.1 Primary outcome   
Admission to intensive care unit or death, within 30 days of admission to hospital.  
6.2.2 Secondary outcomes 
1. Length of stay in intensive care unit 
2. Readmission to hospital within 30 days of hospital discharge 
3. GP consultations within 30 days of hospital discharge 
4. Length of stay in hospital 
5. Death within 30 days of admission to hospital 
6. Admission to intensive care unit within 30 days of admission to hospital 
 
The design and analysis of the trial includes the flexibility to allow for pandemics of different severity. The 
outcome measures described in this section relate to a high-severity pandemic. Further information on the 
outcome measures, including those for a pandemic of low/moderate severity, can be found in section 9. 
 
6.3 Trial Participants  
6.3.1 Overall Description of Trial Participants 
Adults (≥16 years) admitted to hospital with a clinical diagnosis of an influenza-like illness during a 
pandemic. 
6.3.2 Inclusion Criteria 
During an influenza pandemic, patients are eligible for entry into the trial if they: 
 are ≥ 16 years of age 
 have been admitted to hospital within the previous 24 hours with a clinical diagnosis of an influenza-
like illness 
 have given consent (see section 6.4.2) 
6.3.3 Exclusion Criteria 
Patients are not eligible for the trial if ANY of the following apply at the time of admission to hospital: 
 known to be taking oral or IV corticosteroid treatment 
 require treatment with oral or intravenous corticosteroids upon admission to hospital as standard 
treatment for comorbid illness 
 known to be on insulin or oral medication for the treatment of diabetes mellitus 
 known contra-indication to dexamethasone or any of the excipients (please refer to current version of 
SPC)  
 
Where a patient is entered into the trial and later found to meet any of the exclusion criteria detailed 
above, continuation of trial treatment will be discontinued. Data will continue to be collected unless the 
participant specifically withdraws their consent to this. Please see section 7.5 for further information. 
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6.4 Study Procedures 
 
A summary and timing of the study procedures is shown in Table 1. 
 
Table 1: Study procedures and data collection in the ASAP trial 
 
* Data collected at hospital discharge when the discharge is less than 30 days since admission. Data collected at Day 30 if the 
participant is still in hospital at Day 30. 
 
** Not required if participant is hospitalised ≥ 60 days. 
 
# This applies ONLY to those participants that lacked capacity to consent at enrolment. For these participants, written consent must 
be sought as soon as practicable following the emergency treatment and prior to the patient being discharged from hospital 
 
6.4.1 Screening and Eligibility Assessment 
During a pandemic, adults (≥16 years) admitted to hospital with a clinical diagnosis of an influenza-like 
illness and who meet the trial inclusion criteria will be identified by the clinical admitting team. Clinical 
nurses who admit patients with influenza will be trained to provide information about the trial to patients 
and their families.  
 
Pre-prepared advertising material approved by the relevant ethics committee will be used during the 
activation phase to raise public awareness of the trial. 
6.4.2 Consent 
The challenges of obtaining consent for a trial of an acute intervention in an emergency setting within the 
context of a pandemic are recognised. 
 
Assessments 
Day 1 
Screening 
and 
enrolment 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Hospital 
discharge/ 
Day 30* 
Hospital 
discharge + 
30 days 
Screen for eligibility  X       
Obtain written consent X       
Randomise X       
Complete hospital 
admission information X       
Administer trial 
treatment X X X X X   
Obtain written consent# 
for patients that lacked 
capacity at enrolment 
 X# X# X# X# X#  
Collection of  primary 
and secondary 
outcome data from 
hospital notes* 
     X  
Collect  follow-up 
outcomes from postal 
questionnaire 
      X** 
Serious Adverse Event Collect from randomisation throughout trial. See section 8 for information on 
safety reporting requirements. 
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Severe pandemic influenza constitutes a medical emergency; these patients can deteriorate rapidly and 
dramatically – the average time from hospital admission to ICU admission was 1 day in the 2009 
pandemic. In addition, the context of a pandemic means that acute health care resources will be 
exceptionally stretched, through a combination of high healthcare demand and high levels of staff 
sickness. These challenges to the clinical service will also impact significantly on research delivery. 
Recruitment to the ASAP trial must not result in any significant delay to patient care, either to the potential 
participant or to other patients not being approached about the trial. Therefore consent for trial 
participation needs to be integrated into routine clinical care during a pandemic. This means approaching 
patients and their families whilst they are being assessed and triaged at hospital admission, and offering 
participation in a way that minimises disruption to patient care. Thus written consent for the trial will be 
obtained from potential participants using a short, single page combined information sheet and consent 
form at hospital admission points (see Figure 3). A full information leaflet will also be given to participants 
to read at a later time. 
 
Figure 3: Procedure for obtaining consent for the ASAP trial 
  
Potential participant meets
eligibility criteria
Patient has capacity
Written consent
One clinician independent
of the trial to decide in
patient’s best interests
ENROLMENT AND RANDOMISATION
Patient lacks capacity
ENROLMENT AND RANDOMISATION
WRITTEN CONSENT FROM PARTICIPANT (IF CAPACITY
HAS BEEN RECOVERED) OR PERSONAL LEGAL
REPRESENTATIVE* AS SOON AS PRACTICABLE TO DO SO
* Personal Legal Representative can be a partner, friend or relative
Emergency situation in
which it is not medically
appropriate to delay start
of treatment?
Yes
No
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6.4.2.1 Patients with capacity to consent (non-emergency situation) 
During a pandemic the health service will be in crisis, and triage of patients with influenza-like illness at 
hospital admission will mean there will be limited time in which to obtain consent from patients. Thus 
potential participants will have a brief explanation of the trial and be provided with brief written information 
about the trial in the form of a single page combined information sheet and consent form. After the trial 
explanation they will be asked if they are willing to be recruited. If they say yes they will be asked to sign 
the consent form section on the patient information sheet.   
 
Specifically, the responsible doctor or an appropriately trained nurse will explain to the patient that they 
will receive the usual care for influenza but that in addition to this, they can be enrolled in a research study 
that aims to improve the treatment of patients with influenza during a pandemic. It will be explained that 
the study is being undertaken to see whether using a steroid drug called dexamethasone will help patients 
with influenza infection by reducing the number of patients who have severe outcomes (such as death or 
admission to intensive care) or by shortening length of stay in hospital. The doctor or an appropriately 
trained nurse will explain that, in some studies, dexamethasone has been shown to improve outcome for 
patients with pneumonia or severe ‘blood poisoning’, and that whilst we hope it will also improve recovery 
after influenza infection, at present we cannot be sure about this. It will also be explained that if they agree 
to take part in the study, they will be given a liquid solution once a day for 5 days of either dexamethasone 
or placebo orally, or if medicines cannot be taken orally, via a feeding tube. Also, they will be sent a short 
postal questionnaire to complete. 
 
The patient information sheet and consent form will be produced in triplicate copy format; 1 copy for the 
participant, 1 copy for the patient’s medical notes and 1 copy for the Investigator Site File.  
 
The patient will also be given a full information leaflet to keep, which will explain that they can withdraw 
from the trial at any stage, if they wish. 
  
Once written consent has been given, the patient will be randomised (see section 6.4.3) and trial 
treatment commenced. 
 
6.4.2.2 Patient with capacity to consent (emergency situation) 
Where a patient has capacity to consent but is in an emergency situation whereby it is not 
medically appropriate to delay the start of treatment, one independent doctor should consider the 
patient’s eligibility criteria and any known views of the patient about trial participation and decide whether 
or not to enroll the patient into the trial.   
 
Once the decision has been made to enter the patient into the trial this must be documented by the 
clinician in the patient’s medical notes. The participant may then be randomised and trial treatment 
commenced.  Written consent must be sought later (see section 6.4.2.4) 
 
6.4.2.3 Patients without capacity to consent 
 
Patients admitted to hospital with influenza may have impaired consciousness, may be confused, or may 
have an underlying condition such as dementia that impairs their capacity to give properly informed 
consent. In accordance with the regulations concerning emergency situations where the treatment to be 
given as part of the trial needs to be given urgently and time does not allow for consent to be obtained, 
incapacitated patients may be entered into the trial. 
 
 Lack of capacity should be determined by the patient’s attending clinician.  
 
If the patient lacks capacity to give meaningful consent one independent doctor should consider the 
patient’s eligibility criteria and any known views of the patient about trial participation and decide whether 
or not to enroll the patient into the trial.   
 
The consent decision must be documented in the patient’s medical notes. 
 
Once consent has been given, the participant will be randomised and trial treatment commenced. Written 
consent must be sought later (see section 6.4.2.4) 
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6.4.2.4 Written consent for patients that lacked capacity at enrolment and emergency situations 
 
For patients that lack capacity to consent at enrolment or patients with capacity that are entered into the 
trial under emergency situation regulations, written consent must be obtained by a doctor or appropriately 
trained nurse from the participant (if capacity has been recovered) or Personal Legal Representative as 
soon as it is practicable to do so.  
 
A Personal Legal Representative may be a partner, friend or relative. 
 
The participant’s decision to withdraw would overrule any decision made by a doctor or Personal Legal 
Representative. 
 
6.4.3 Randomisation  
Batches of treatment packs will be supplied directly to trial sites from one or more manufacturing units. 
Each batch will contain a number of sealed treatment packs in a consecutively numbered series.  
 
The following will be included in the treatment pack: 
 A 75ml bottle of either dexamethasone 2mg/5ml or placebo (sufficient for 5 days of treatment) 
 Instructions for the take home pack (for participants discharged within 5 days of admission) 
 Administration instructions 
 A spoon for drug administration 
 A trial wristband to enable identification of trial participants during hospital transfers 
 
Trial treatment packs will be available in each area where patients with influenza will be admitted during a 
pandemic. The two treatments, dexamethasone and placebo, will be indistinguishable. Each treatment 
pack will be labelled with the trial name and a unique identification number. This will be the Participant’s ID 
Number. NCTU will generate and hold the randomisation sequence according to their SOP.  
 
Once consent for trial participation has been obtained, allocation to trial treatment will be by taking the 
next in the series of treatment packs at that area each participating site. The trial pack label will be 
completed and the trial treatment prescribed. 
 
Treatment will be administered as soon as possible, as an addition to standard care. 
 
Participants will be considered to be in the trial once the pack label has been completed 
regardless of whether or not they take any allocated treatment. 
 
Packs which have been tampered with will be removed from the trial, and any packs used out of sequence 
will be investigated to ascertain why this happened and whether there was any potential for bias.  
The following steps will be taken to guard against participants being randomised into the study more than 
once: 
 
        Site staff obtaining consent from trial participants at hospital admission points will be trained 
to ask patients if they have previously participated in the study. 
        Reminders of the need to check with patients about previous participation in the study will be in 
place for clinical staff at hospital admission points. 
 
However given the mechanism of randomisation and the circumstances in a pandemic, it is not possible to 
completely remove the possibility that someone could be randomised more than once. The analytical 
approach to deal with this is described in section 9.1. 
 
6.4.4 Collection of hospital admission data 
Once consent has been obtained, routinely available data recorded in hospital notes at the time of hospital 
admission will be recorded on the Case Report Form (CRF) by site staff. This will include patient contact 
details, patient demographics, time of onset of symptoms, prior treatment, routinely collected clinical 
observations and test results. 
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6.4.5 Subsequent assessments 
Participants will not have any additional study visits. Data will be collected as follows:  
 
Hospital discharge or Day 30 
At hospital discharge, or Day 30 if the participant remains in hospital, outcome data will be collected from 
the medical notes by research staff at site and recorded on the CRF. This will include patient discharge 
status, critical care admission, in-hospital treatments including IMP compliance and relevant routinely 
obtained microbiological test results. 
 
A regular check of hospital systems will need to be performed by site staff to ascertain patient status, 
including outcome information for those patients hospitalised ≥60 days. 
 
Follow-up 
Participants will be asked to complete a postal follow-up questionnaire 30 days after being discharged 
from hospital. For any participant who remains hospitalised at Day 60 no follow-up questionnaire is 
required.  
 
The questionnaire will ask about any GP consultations or hospital readmissions within 30 days of 
discharge from hospital. In addition, for participants who are discharged within 5 days of admission and 
given their trial treatment to take home, information about treatment compliance will also be requested. 
The questionnaire will be posted from the NCTU to trial participants, with a prepaid and addressed 
envelope to return to the NCTU.  
 
Any participants who do not return the questionnaire within 14 days of the due date for completion will be 
contacted by telephone by the NCTU.  The participant will be considered lost to follow-up if the 
questionnaire is not returned, and they have either not been contactable by telephone or have declined to 
complete the questionnaire by telephone. 
 
Identifiable data will be collected for the purpose of the follow-up and the patient’s details will be registered 
with the Health and Social Care Information Centre (HSCIC) to find out how they are doing after they have 
left hospital. 
 
6.4.6 Maintenance of randomisation codes and procedures for unblinding 
Clinicians, participants and outcome assessors (research team) will be blinded to the treatment allocation.  
 
The randomisation schedule will be stored centrally on a restricted area of the university’s network 
storage. Access will be restricted to the IT team at the NCTU and central university Information Services’ 
support staff. The research team will not have access to this. 
 
In general there should be no need to unblind the allocated treatment. If a contra-indication to 
dexamethasone develops after randomisation (e.g. evidence of severe drug reaction), the trial treatment 
should simply be stopped. Unblinding should happen only in those rare cases where the doctor believes 
that clinical management depends importantly upon knowledge of whether the participant received 
dexamethasone or placebo. In those few cases where urgent unblinding is considered necessary, the date 
and reason for breaking the code will be recorded. It is recommended that any decision to unblind is 
discussed with the coordinating centre prior to this being done.  
 
An emergency 24 hour trial contact number for unblinding purposes will be supplied to trial sites upon 
activation of the trial. 
 
6.5 Definition of End of Trial  
The end of trial is the date of receipt of the last follow-up information (questionnaire or, for any patient 
hospitalised more than 60 days, the date of obtaining patient outcome data from hospital-based system 
records). 
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6.6 Discontinuation of trial treatment or withdrawal of participants 
Each participant has the right to withdraw from the study at any time. In addition, the investigator may 
discontinue study treatment at any time if they consider it necessary for any reason including: 
 Ineligibility (either arising during the study or retrospective having been overlooked at enrolment) 
 Disease progression which requires discontinuation of the study medication or results in inability 
to continue to comply with study procedures 
 Consent withdrawn 
 
6.6.1 Discontinuation of trial treatment 
A participant may discontinue treatment either at their own request, or if it is felt in their best interest by the 
attending clinician. A participant who discontinues treatment (for whatever reason) will remain in the trial 
for the purpose of collection of follow-up data, unless they have specifically requested withdrawal from 
further follow-up (see section 6.6.2).  
 
Each participant has the right to discontinue trial treatment at any time. If this happens, they will receive 
standard care. Participant’s data will be analysed in their allocated group as “intention to treat” regardless 
of whether or not they received the intervention. 
6.6.2 Withdrawal from the trial 
Each participant has the right to withdraw from the study at any time. For those participants without 
capacity to consent to the trial at the time of admission and who were consented by a legal representative, 
withdrawal from the trial may either be at the participant’s own request (if they regain capacity) or at the 
request of their relative /legal representative. The participant and the relative/legal representative will be 
made aware that this will not affect the participant’s future care.  
 
The reasons for leaving the study will be requested and recorded, but participants are not obliged to give 
reasons. Participants will be assured that withdrawal will not affect the future care they receive. They will 
be informed that data collected up to the point of withdrawal will be retained and may be used in the final 
analysis and that their NHS number will be registered with the Health and Social Care Information Centre 
(HSCIC) to follow them up after they leave hospital (unless specifically requested not to do so), but they 
will not be directly contacted for the purpose of obtaining follow-up information.. There will be no 
replacement of participants who withdraw.  
6.7 Source Data 
Source documents are original documents, data, and records from which participants’ CRF data are 
obtained.  These include, but are not limited to, hospital records and clinical charts. 
 
CRF entries will be considered source data if the CRF is the site of the original recording (e.g. there is no 
other written or electronic record of data). In this trial the follow-up questionnaire will be used as the 
source document for obtaining information about secondary outcome measures (re-admission to hospital 
and/or consultation of GP within 30 days of hospital discharge). 
 
All documents will be stored safely in confidential conditions.  On all study-specific documents, other than 
the signed consent document, the participant will be referred to by the unique participant ID number, not 
by name. 
 
7 TREATMENT OF TRIAL PARTICIPANTS 
7.1 Description and manufacture of trial treatment 
 
Intervention:  Dexamethasone 6 mg as a liquid solution (15ml) once daily for 5 days, administered orally 
or via enteral feeding tube.  
 
Control:   Matched placebo solution (15ml) once daily for 5 days, administered orally or via enteral 
feeding tube. 
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Dexsol (Dexamethasone) 2mg/5ml Oral Solution manufactured by Rosemont Pharmaceuticals Ltd (PL 
00427/0137) will be used in this trial. Rosemont will also manufacture a matching placebo formulation.  
 
Inactive ingredients in the trial treatment (active and placebo): Benzoic acid, propylene glycol, citric 
acid monohydrate, liquid maltitol, garden mint flavour (containing isopropanol and propylene glycol), liquid 
sorbitol non-crystallising, sodium citrate and purified water. 
7.1.1 Dosage 
Participants will receive 15ml dexamethasone (6 mg) or placebo as a liquid solution once daily for 5 days, 
administered orally or via a nasogastric feeding tube. 
 
All other care will be according to national clinical management guidelines for pandemic influenza 
 
First dose of IMP 
The first dose of IMP should be given as soon as possible after consent for trial participation has been 
obtained, regardless of the time of day. 
 
Subsequent doses of IMP 
The date when the first dose of IMP is given to the trial participant should be considered as Day 1 of IMP 
treatment regardless of the time the dose was given.  The second dose of IMP should not be given until 
the following day (Day 2), preferably in the morning.  Further doses should ideally be given each morning. 
 
Please note that this means for any patient receiving their first dose of IMP in the early hours of the 
morning (Day 1), the dose interval between first and second dose will be more than 24 hours. For those 
patients randomised late evening, the second dose will be given the following morning and thus the dose 
interval will be shorter, however this is not expected to be less than 8 hours. 
7.1.2 Packaging and Labelling 
Rosemont will ship bulk supply of dexamethasone and placebo  to one or more manufacturing units, who 
will be set up to provide the randomised final labelling, packaging and release service in order to ensure 
the short timeline from activation to the start of trial recruitment is met. 
 
The manufacturing units will receive bulk active and placebo bottles from Rosemont.  They will over-label 
a single 75ml bottle according to Annex 13 and pack with written instructions in a clear outer pack so that 
the primary packaging label can be read through the pack.  
 
The final product will be QP released by the designated person at the manufacturing unit.  
 
An outer dispenser pack will be assembled containing, in number order the finished active and placebo 
packs. This will allow the trial treatment packs to be removed from the dispenser in sequence order.  
  
The manufacturing unit where the packaging and release occurs will distribute trial supplies to 
participating sites. 
 
7.2 Storage of Trial Treatment 
The trial treatment will be received and stored by the main pharmacy at each hospital for distribution to the 
point(s) of patient admission within the hospital. Each participating site main hospital pharmacy will take 
receipt of numbered supplies from one of the manufacturing units. 
 
Trial treatments will be stored at room temperature below 30 ºC. In the local pharmacy, all trial treatments 
should be stored in a secure location. The main hospital pharmacy will supply batches of individual 
participant packs to Admission Points: areas within their hospital where influenza admissions occur.  
 
7.3 Compliance with Trial Treatment 
Compliance with trial treatment for hospitalised participants will be assessed from their medication chart 
which nursing staff will complete. This information will be collected and recorded on the CRF. If the 
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participant is discharged before 5 days, they will be instructed to complete their trial treatment at home. 
Compliance with study medication following discharge will be obtained from information requested in the 
follow-up postal questionnaire.  
 
Compliance with trial treatment is expected to be good.    
 
7.4 Accountability of the Trial Treatment 
The participant packs of trial treatment will be supplied by the manufacturing units to the main hospital 
pharmacy at participating sites.  All movements of study medication between the manufacturing units and 
main hospital pharmacies will be documented. The main hospital pharmacies will record the distribution of 
all trial medication to the admission points within the hospital. 
 
An accountability log will be maintained at each admission point within the hospital and will be completed 
upon allocation of trial treatment pack to a participant. Completed accountability logs will be returned to 
the main hospital pharmacy. 
 
Unused participant packs will be retrieved and accountability completed, before local destruction. 
 
7.5 Concomitant Medication 
Throughout the trial investigators may prescribe any concomitant medications or treatments deemed 
necessary to provide adequate supportive care except for those listed in the exclusion criteria (see section 
6.3.3). If these are required during the five days of IMP administration, the participant will be withdrawn 
from the trial treatment. 
 
The following specific medications, other than the trial treatment, taken during the study will be recorded in 
the CRF: 
 
a) antiviral drugs 
b) antibiotics 
c) corticosteroids given after completion of trial treatment  
 
8 SAFETY REPORTING 
The definition of a serious adverse event (SAE) is problematic in the context of the ASAP trial since 
participants are likely to be critically ill patients and progression of pandemic influenza can lead to 
significantly life threatening and serious conditions, which are outcomes for this trial. 
 
Events that are part of the natural history of the primary disease process or expected complications of 
critical illness will not be reportable as serious adverse events. 
 
The principal investigator at a site will need to distinguish between an SAE that is possibly, 
probably or definitely related to treatment (i.e. a suspected adverse reaction (SAR) – see definition 
below) and an SAE that arises from disease progression or has another cause. 
 
The study intervention (dexamethasone) is a commonly used drug for which the safety profile is well 
established. For this reason, only serious unexpected suspected adverse reactions (SUSARs) 
should be reported on an SAE form for this trial. 
 
The trial will also capture other serious adverse events (SAEs), which are pre-specified outcomes in the 
trial. These will not be reportable on an SAE form but will be captured on the CRF and include the 
following: 
 
 Death due to progression of the underlying disease or co-morbid illness 
 Admission to the intensive care unit due to progression of the underlying disease or co-morbid 
illness 
 Prolongation of hospital stay due to progression of the underlying disease or co-morbid illness 
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8.1 Definitions 
8.1.1  Serious Adverse Event (SAE) 
A serious adverse event is any untoward medical occurrence in a patient administered a medicinal 
product, which does not necessarily have to have a causal relationship with the treatment (the study 
medication) that at any dose: 
 Results in death, 
 Is life-threatening (NOTE: The term "life-threatening" in the definition of "serious" refers to an event in 
which the participant was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe.) 
 Requires inpatient hospitalisation or prolongation of existing hospitalisation, 
 Results in persistent or significant disability/incapacity, or 
 Is a congenital anomaly/birth defect. 
 Other important medical events (NOTE: Other events that may not result in death are not life 
threatening, or do not require hospitalisation, may be considered a serious adverse event when, 
based upon appropriate medical judgement, the event may jeopardise the patient and may require 
medical or surgical intervention to prevent one of the outcomes listed above.) 
 
8.1.2 Serious Adverse Reaction (SAR) 
All untoward and unintended responses to a medicinal product related to any dose. 
 
The phrase "responses to a medicinal product" means that a causal relationship between a study 
medication and an AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out.  
 
All cases judged by either the reporting medically qualified professional or the sponsor as having a 
reasonable suspected causal relationship to the trial treatment qualify as adverse reactions.   
 
8.1.3 Expected Serious Adverse Reactions (Expected SAR) 
An adverse reaction, the nature or severity of which is consistent with the applicable product information. 
 
8.1.4 Suspected Unexpected Serious Adverse Reactions (SUSARs) 
A serious adverse reaction, the nature or severity of which is not consistent with the summary of product 
characteristics. Dexamethasone is an established drug with a well-known safety profile and therefore the 
occurrence of SUSARs in this trial is unlikely. 
 
8.2 Reporting procedure  
Serious unexpected adverse reactions (SUSARs) are expected to be rare in this trial, however all 
SUSARs should be reported on an SAE form within 24 hours of being made aware of the event to the 
Sponsor. 
 
The fax number for reporting of SUSARs will be supplied to trial sites once the decision to activate the trial 
has been made. 
 
All other serious adverse events and serious adverse reactions will not be reported. Where they are a pre-
specified outcome for the trial they will be collected on the CRF.  
 
The flow chart in  
 
Figure 4 should be used to determine whether an SAE requires reporting on an SAE form. 
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Figure 4: Flowchart for reporting of serious adverse events 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serious Adverse Event
Related to IMP?
Unexpected?*
SUSAR
Report on SAE form
within 24 hours
No
Do not report.
If event is a pre-specified
outcome it will be
captured on the CRF
* the event is not consistent with the summary of product characteristics
Serious Adverse Reaction
(SAR)
Yes
Yes
No
Do not report.
If event is a pre-specified
outcome it will be
captured on the CRF
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9 STATISTICAL CONSIDERATIONS 
 
A separate detailed statistical analysis plan will be written and approved by the Trial Steering Committee 
during the set up phase. The trial is planned in anticipation of a high severity pandemic; this represents 
the most challenging situation for trial execution and also the situation in which the trial results might have 
the largest public health impact. At the outset of a pandemic, its severity will not necessarily be accurately 
appreciated. The statistical plan therefore includes the flexibility to address pandemics of different 
severity. A review of pandemic severity will be conducted by the TSC as the pandemic unfolds. Decisions 
regarding the final analysis plan and final primary outcome will rest with the TSC. A summary of the plan is 
described below. 
 
9.1 Description of Statistical Methods 
We will compare numbers, age and sex of randomised participants with aggregate summary data of all 
patients admitted to hospital with influenza-like illness during the study period. We will compare baseline 
characteristics of the randomised arms using appropriate descriptive statistics. Between-group 
comparisons for primary and secondary outcomes will be conducted using an intention-to-treat (ITT) 
approach, implemented using appropriate regression models, and with results presented as point 
estimates such as a ratio or difference comparing dexamethasone with placebo, with 95% confidence 
intervals, and exact p-values. Secondary analyses will include additional adjustment for variables 
displaying an important imbalance at baseline. We anticipate little, if any, missing primary outcome data 
and therefore will use ITT without imputation as the main approach, and will investigate the influence of 
any missing data in sensitivity analyses, including multiple imputation. A definition of the pandemic as 
high, moderate or low severity is expected soon after the end of the first wave, and analysis of the 
appropriate primary outcome, and such secondary outcome data as are available, will then ensue in time 
to inform subsequent pandemic waves.  All analyses will be conducted using Stata version 11.2 or higher, 
or MLwiN 2.10 or higher. 
 
It is possible that a small number of participants will be randomised more than once. We will examine 
baseline (at first randomisation) characteristics and previous treatment allocation(s) of participants 
randomised more than once using appropriate descriptive statistics. The primary analysis will use 
treatment allocation and date of the first randomisation. In sensitivity analyses, we will (1) further adjust for 
variables associated with multiple randomisation (baseline characteristics and initial treatment allocation), 
and (2) use treatment allocation and date of the last randomisation. 
 
High Severity Pandemic 
In a high severity pandemic, the primary composite outcome is admission to intensive care or 
death by Day 30, and will be analysed using generalised linear modelling for binary outcomes, also 
allowing for stratification by site.  Additionally, death will be reported alone as a secondary outcome. 
 
Low/Moderate Severity Pandemic 
In a low/moderate severity pandemic, the primary outcome is time to hospital discharge, right-
censored at 30 days, and will be analysed using appropriate (dependent on distribution of the outcome) 
time-to-event regression modelling, also allowing for stratification by site and for the occurrence of death 
prior to hospital discharge as a competing event. 
 
Pre-planned sub-group analyses will be conducted for the primary outcome based on the following 
baseline factors: 
1) Duration of symptoms before trial entry: less than 4 days; more than 4 days; not known  
2) Clinical diagnosis of pneumonia at trial entry: pneumonia; no pneumonia; not known 
3) Underlying co-morbid illness at trial entry (defined as any medical illness requiring active regular 
treatment): underlying co-morbid disease, no underlying co-morbid disease; not known 
4) Severity of influenza at trial entry (severe influenza defined as the presence of 3 or more 
community triage criteria [28]): severe influenza; not severe influenza; severity unclear/ not 
known. 
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Outcomes will be reported descriptively by sub-group category and treatment arm, and formally estimated 
by fitting interaction terms in the regression models. It is recognised that power to detect sub-group effects 
is likely to be low, and these analyses will be regarded as exploratory and interpreted with due caution.  
9.2 The Number of Participants 
The planned sample size of 2200 patients is based on a high severity pandemic along a range of possible 
scenarios.  This flexibility is important as the accuracy of the modelling may only become clear as the 
pandemic unfolds.  
 
Based on data from the Department of Health, modelling estimates are that, for a high severity pandemic, 
35% of those admitted to hospital will die and 25% will be admitted to intensive care.  Of those admitted to 
intensive care, an estimated 50% will die (estimate derived from UK data related to the 2009 pandemic 
and to community acquired pneumonia). Thus 47.5% will have the composite outcome of death or 
admission to hospital in the control group. For this scenario, our study would have 90% power to detect a 
15% reduction in relative risk of the composite outcome associated with steroids, and a 20% reduction in 
deaths. Since a high proportion of those admitted to hospital will die and admissions to intensive care will 
also be high, therefore, an effect size of 15% would be clinically important.  
 
Table 2 presents a range of scenarios centres around a control event rate of 47.5%. 
 
Table 2: Sample size calculations for a high severity pandemic 
Control  
event rate 
Relative risk reduction 
with dexamethasone 
treatment 
N* 
(80% power) 
N* 
(90% power) 
35% 
20% 
15% 
1514 
2704 
2006 
3592 
40% 
20% 
15% 
1242 
2210 
1644 
2932 
47.5% 
20% 
15% 
940 
1662 
1242 
2204 
50% 
20% 
15% 
860 
1514 
1134 
2010 
* Sample size estimates in each cell have been inflated by 5%, to allow for lack of compliance and loss to 
follow-up (both anticipated to be low) 
 
For low and moderate severity pandemics, a Hazard Ratio of 1.25, indicating an increased risk of 
discharge at any given time, is considered as the minimum clinically relevant change to detect. The 
sample size estimation method is the log rank test allowing for competing risks, and assumes that in the 
control group 5% are censored at 30 days, and in both groups, 6% (low severity pandemic) and 10% 
(moderate severity pandemic) die during hospitalisation. With 90% power and 1% two-side alpha, and 
allowing for 5% non-collection of primary outcome data, a total of 912 and 924 participants are required to 
be randomised for low and moderate severity pandemics respectively. 
 
The target sample size for the study is 2200. If the pandemic is of low or moderate severity, it is likely that 
fewer than 2200 participants will be randomised during the first wave of approximately six weeks duration, 
although this definition will not be available until after the end of the first wave. If more than 924 
participants are randomised in a low/moderate severity pandemic then smaller effect sizes may be 
detectable. 
 
9.3 Interim Analyses 
The objective of the trial is to complete recruitment within the first pandemic wave. Typically, a pandemic 
wave is of 6 weeks’ duration. Therefore, it is expected that there will be insufficient time to perform a 
meaningful interim analysis based on efficacy data prior to close of recruitment. An early analysis will be 
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conducted at the close of recruitment and before the second pandemic wave. Given the timeframes 
involved, this early analysis will report on the primary outcome and as many other outcomes as possible. 
 
9.4 Procedure for accounting for missing, unused, and spurious data. 
The reason for missing data will be checked. Sensitivity analysis will be performed prior to imputation of 
missing data. If imputation is required, multiple imputation will be considered if data missing are at 
random. Otherwise, a selection bias collection model within a mixture model framework will be considered.  
 
Both missing data and spurious data will be queried.  
 
10 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
Direct access will be granted to authorised representatives from the sponsor, NCTU, host institution and 
the regulatory authorities to permit trial-related monitoring, audits and inspections. 
 
11 QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES 
The study will be conducted in accordance with the current approved protocol, ICH GCP, relevant 
regulations and standard operating procedures.  
 
Data will be evaluated for compliance with the protocol and accuracy in relation to source documents. 
Following written standard operating procedures, the monitors will verify that the clinical trial is conducted 
and data are generated, documented and reported in compliance with the protocol, GCP and the 
applicable regulatory requirements.  
 
A Trial Steering Committee (TSC) has been established which includes an independent chair, two 
independent members and patient representatives.  The TSC will meet to discuss and agree the final 
protocol version, and it will approve the Statistical Analysis Plan before the trial data are unblinded.  
 
The TSC have agreed to meet (either in person or by telephone) every three years during the hibernation 
phase. A yearly report will be produced by the TMG and sent to the TSC. Should any of the information 
contained in the report warrant a meeting this will be arranged. 
 
The TSC will be responsible for activating the trial in consultation with the TMG, NIHR and Department of 
Health.   
 
An independent Data Monitoring Committee (DMC) will be established and will act in accordance with the 
pre-agreed terms of reference. Only the DMC will have access to unblinded data until the final 
assessment has been completed.  
 
The Trial Management Group (TMG) will be responsible for day-to-day supervision of the study. 
Membership will include the CI, the trial manager and at least one other member of the NCTU. The TMG 
will be responsible for ensuring project milestones are achieved. The TMG will meet monthly during the 
set up phase, 6 monthly during the ‘hibernation’ phase, and every 2 to 8 weeks during the activation 
phase (depending on need). The TMG will report at least annually to the TSC.  
 
Recruitment rates at sub-study sites will be monitored closely by the Trial Management Group 
TMG and TSC. 
12 ETHICS 
12.1 Declaration of Helsinki 
The Investigator will ensure that this study is conducted in full conformity with the current revision of the 
Declaration of Helsinki (last amended October 2000, with additional footnotes added 2002 and 2004). 
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12.2 ICH Guidelines for Good Clinical Practice 
The Investigator will ensure that this study is conducted in full conformity with relevant regulations and 
with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996. 
12.3 Approvals  
Trial documents including the protocol, consent documentation, participant information sheet, postal 
questionnaire and any proposed advertising material will be submitted to an appropriate Research Ethics 
Committee (REC). Required documents will also be submitted to the regulatory authorities (MHRA in the 
UK), and host institution(s) for written approval.  
 
The Investigator will submit and, where necessary, obtain approval from the above parties for all 
substantial amendments to the original approved documents.    
12.4 Participant Confidentiality 
The trial staff will ensure that the participants’ anonymity is maintained.  Each participant will be assigned 
a Participant ID number, allocated at randomisation, for use on trial documents and the trial database. The 
documents and database will also use the patient’s initials. The patient’s date of birth will also be entered 
into the database.  
 
The participants will be identified only by participant ID number on the trial database and on the follow-up 
questionnaire returned to the NCTU.  All documents will be stored securely and only accessible by trial 
staff and authorised personnel. The study will comply with the Data Protection Act.  
12.5 Other Ethical Considerations 
There are no additional ethical considerations.  
 
13 DATA HANDLING AND RECORD KEEPING 
 
All trial data will be entered onto a trial specific macro system, via a secure web browser session. Access 
to the system will be restricted and secure using password protection. All data will be stored on a secure 
server. Access will be restricted by user identifiers and passwords. 
 
Electronic data will be backed up every 24 hours to a remote secure encrypted server. 
 
For the follow up questionnaire and registration of participants with the HSCIC, identifiable information 
about participants will be held in a separate area of the system. Access to this information will be 
restricted to those involved in the follow up phase, as authorised by the Chief Investigator. Only the 
participant number will be used on the follow up questionnaire that will be posted back to NCTU. 
 
14 FINANCING AND INSURANCE 
 
This study is funded through the NIHR Programme NETSCC Pandemic Flu personal award (11/46/14). 
Nottingham University hospitals NHS Trust will act as the main sponsor for this trial. Delegated 
responsibilities will be assigned to the NHS trusts taking part in this trial.  Standard NHS Indemnity 
applies. 
 
15 PUBLICATION POLICY 
 
The study has been designed and will be reported according to the CONSORT guidelines. The findings 
from this study will provide robust evidence for clinicians working in acute medical services including 
Emergency Departments. Findings will be published in peer-reviewed scientific journals, medical society 
newsletters and where possible in the local press and media. The results will be presented at national and 
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international conferences. Participants who requested a copy of the report will be sent a lay summary of 
the study 
 
16 HEALTH ECONOMICS 
 
A provider perspective for costs will be adopted.  For patients in both the test and the control arms, 
management will entail up to 4 different episodes of hospital stays, plus primary care visits following 
discharge.  The cost for each patient is therefore the sum of the following (where IP = inpatient, LOS = 
length of stay, in days). 
 Cost of initial IP admission = cost of IP stay per diem * LOS1. 
 Cost of readmission = cost of IP stay per diem * LOS2. 
 Cost of intensive/critical care = cost of ICU per hour * LOS3 * 24 
 Cost of intervention-related complications = cost of IP stay per diem * LOS4. 
 Primary care costs = cost per GP consultation * number of condition-related consultations. 
 
The trial will record the 4 types of IP LOS and GP visits for each patient, enabling calculation of patient 
specific health system costs (following multiplication by the appropriate units costs).   
 
For patients admitted to critical care, separate national tariffs for critical care which have been developed 
in relation to the number of organs supported (zero to six, reference costs currency codes XC07Z to 
XC01Z) will be used to attribute critical care costs weighted by degree of support to each subject under 
treatment.  
 
From a health outcome point of view, the only difference between the trial arms will be in their death rates.  
Given the age at death for each patient, the expected total and average life years lost in each arm using 
conventional life-tables will be calculated. 
 
The results will be expressed as the: 
 Average management cost per patient for each arm. 
 Incremental cost-effectiveness ratio (mean cost per life year gained, test arm relative to control). 
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APPENDIX A – TRIAL FLOW CHART 
 
ALLOCATION: SEQUENTIALLY NUMBERED TRIAL DRUG 
PACKS AVAILABLE LOCALLY 
OUTCOMES 
EXCLUSION CRITERIA: taking or 
requiring oral/IV steroids; on insulin or 
oral medication for diabetes; 
contraindication to dexamethasone 
ANALYSIS BY INTENTION TO TREAT 
ASSESSED FOR ELIGIBILITY: ADULTS (≥ 
 16 YEARS) PRESENTING TO HOSPITAL 
WITH AN INFLUENZA-LIKE ILLNESS 
DURING A PANDEMIC 
ALLOCATED TO DEXAMETHASONE 
(n=1100) 6 mg daily for 5 days. Remainder of 
patient care as per national guidelines.  
ALLOCATED TO MATCHED PLACEBO 
(n=1100) daily for 5 days. Remainder of 
patient care as per national guidelines.  
PRIMARY OUTCOME: Proportion admitted to intensive care or died within 30 days of admission to hospital 
 
Secondary outcomes: Length of hospital stay; Death during hospital stay and within 30 days of discharge; 
Length of stay in intensive care unit >7 days; Readmission within 30 days of hospital discharge; General 
Practitioner consultation within 30 days of hospital discharge. 
FOLLOW UP 
POSTAL QUESTIONNAIRE: 30 days following hospital discharge (and telephone follow up of non-responders 14 
days later) to determine GP re-consultation and hospital readmission rates. 
AT THE OUTSET OF A PANDEMIC, ITS SEVERITY WILL NOT NECESSARILY BE ACCURATELY 
APPRECIATED. As the pandemic progresses a review of pandemic severity will be conducted by the TSC. 
Decisions regarding the final analysis plan will rest with the TSC 
PERMUTED BLOCK RANDOMISATION  
(n= 2200) with parallel group design 
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APPENDIX B – MECHANISTIC SUB-STUDY: DETERMINING THE 
INTERACTION OF STEROID THERAPY AND THE HOST 
 
PLEASE NOTE THAT THIS SUB-STUDY WILL ONLY BE CONDUCTED AT THE FOLLOWING SITES: 
 
1) Aintree University Hospital, Liverpool 
2) City Hospital, Nottingham 
3) Manchester Royal Infirmary 
4) Queen’s M edical Centre, Nottingha m 
5) Royal Liverpool University Hospital 
6) Southampton General Hospital 
 
 
 
 
Aims 
This mechanistic sub-study aims to address the following key questions in the treatment of influenza: 
 
a) For each patient, what was the point in the natural history of influenza infection at which admission 
occurred? 
b) What effect dose steroid have on the natural history of influenza infection defined by clinical 
phenotype and RNA transcriptomic pattern? 
c) Does comparison of the transcriptomic pattern in placebo versus steroid treated arm suggest pro-
inflammatory and anti-inflammatory mechanisms are both altered? 
 
Background 
The NIHR have recommended that a mechanistic sub-study be conducted as part of the ASAP trial. This 
sub-study will be conducted in a limited number of pre-selected ASAP trial sites. These sites have been 
selected as they are considered to have sufficient staff and infrastructural capacity to manage the 
additional work related to the sub-study without compromise to clinical care delivery or conduct of the 
main ASAP trial. 
 
The onset of symptoms is highly variable in influenza exposed adults1 and the severity of symptoms is the 
result of a complex host-pathogen interaction2 altered by co-infection and co-morbid illness3. Initially, 
cytokine data were used to describe this interaction, but recent data from a unique human influenza 
challenge study have fully described the human inflammatory and anti-inflammatory pathways that 
determine symptom severity in exposed adults4. Using whole genome arrays (Affymetrix Human Genome 
U133A v2), 5076 genes showed altered expression during the 5 days following influenza A exposure. 
Unsupervised and clinically informed analyses resulted in self-organising maps (clustered gene 
expression patterns) which showed 8 functionally important gene sets in which activation/inhibition was 
tightly associated with clinical severity (see reference 4). The study also described the duration in hours 
between virus exposure and significant difference in self-organising map (SOM) cluster expression 
between symptomatic/asymptomatic subjects. 
 
Thus, this sub-study will apply the best contemporary (with respect to the time of pandemic declaration) 
methods to a representative sample (n=200) of ASAP trial participants in order to determine the interaction 
of steroid therapy and the host and to apply this in interpreting the clinical outcome measured. 
  
IMPORTANT: THIS APPENDIX IS ONLY APPLICABLE TO THE ABOVE LISTED SITES. 
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Methods/Design 
Patients recruited into the ASAP trial at the sub-study sites will be given the opportunity to participate in 
the sub-study. 200 patients who have received ASAP study medication are required for the sub-study. 
 
ASAP trial participants who consent to participation in the sub-study will give two blood samples and have 
one nasal swab taken for subsequent transcriptomic and microbiological testing. Blood samples will be 
collected into vaccutainer tubes at baseline and 48 hours post first dose of ASAP study medication. These 
time points are practical and match the best available transcriptomic data and the expected time course of 
steroid effect on gene expression. These samples can be collected using standard venesection methods 
and transferred without urgency to frozen storage in the hospital clinical laboratories. These sample 
collections should therefore be minimally obstructive in the context of a pandemic. The nasal swab for 
virological confirmation will be obtained at the time of the first blood sample collection. Please see figure 1 
for an overview of the sub-study design. 
 
The overarching principle in relation to the conduct of the mechanistic sub-study is that it should not 
disadvantage or jeopardise conduct of or recruitment into the main ASAP trial. Six sites have been 
selected to participate in the sub-study and the decision to activate the sub-study and  these sites will be 
determined by the Trial Management Group according to pre-agreed criteria. The  ability of these sites to 
conduct the sub-study will continue to be monitored by the Trial Management Group throughout the 
recruitment phase. 
 
Figure 1: Overview of the sub-study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Admission to hospital with
influenza-like illness during
pandemic and recruited into
ASAP Trial
Obtain consent for
participation in sub-study*
Obtain 16 ml peripheral
blood and nasal swab before
or within 4 hours of first
dose of ASAP study
medication being given
* Blood and nasal samples are required at the latest 4 hours aer ﬁrst dose of study medicaon so consent must 
have been obtained prior to the samples being taken.
#
Sample should be obtained at 48 hours (+/- 3 hours) or at discharge if this is sooner
Obtain 20ml peripheral blood
48# hours after 1st dose of
ASAP study medication
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Participants and recruitment 
All patients recruited into the ASAP trial at sub-study sites will be eligible to participate in the sub-study.  
 
In order to fulfil the sampling requirements, recruitment into the sub-study should only be considered 
where it is practically possible to obtain consent for the sub-study and take the first blood sample 
required for the sub-study either before the participant receives their first dose of ASAP study 
medication or within 4 hours of the first dose of ASAP study medication being administered.  
 
ASAP trial participants will be approached by a doctor or nurse following consent into the ASAP trial, 
either at the point of recruitment into the ASAP trial or shortly after being recruited into the ASAP trial. 
 
Consent must be obtained for all patients recruited into the sub-study in a similar manner as for the ASAP 
trial to ensure a representative sample of participants. 
 
A separate sub-study patient information sheet and consent form will be used. 
 
The procedure for obtaining consent for the sub-study is as follows: 
 
Patients with capacity to consent (non-emergency situation) 
ASAP trial participants will be provided with a sub-study patient information sheet and a doctor or nurse 
will give a verbal explanation of the study. It will be clearly stated that the patient is free to withdraw from 
the sub-study at any time and for any reason without affecting their future care, and with no obligation to 
give the reason for withdrawal. The ASAP trial participant will be given the opportunity to ask any 
questions and if they agree to participate in the sub-study they will be asked to sign a consent form. The 
participant must personally sign and date the latest approved version of the informed consent form before 
any sub-study procedures are performed. The person obtaining consent must be suitably qualified and 
experienced, and have been authorised to do so by the ASAP Trial Principal Investigator.  
 
Once written consent has been obtained, the patient will be enrolled onto the sub-study. 
 
Patients with capacity to consent (emergency situation) 
In the same manner described in the ASAP trial protocol, where a patient has capacity to consent but is in 
an emergency situation whereby it is not medically appropriate to delay the start of the ASAP study 
treatment, one independent doctor should consider the patient’s eligibility criteria and any known views 
of the patient about participation and decide whether or not to enrol the patient into the sub-study. 
 
Once the decision has been made to enter the patient into the sub-study this must be documented by the 
clinician in the patient’s medical notes. The participant may then be enrolled into the sub-study. Written 
consent must be sought later.  
 
Patients without capacity to consent 
If, in accordance with the ASAP trial protocol a patient is judged to lack capacity to consent, one 
independent doctor should consider the patient’s eligibility criteria and any known views of the patient 
about participation and decide whether or not to enrol the patient into the sub-study. 
 
Once the decision has been made to enter the patient into the sub-study this must be documented by the 
clinician in the patient’s medical notes. The participant may then be enrolled into the sub-study. Written 
consent must be sought later.  
 
Written consent for patients that lacked capacity at enrolment and emergency situations 
For patients who lack capacity to consent at enrolment or patients with capacity that are entered into the 
trial under emergency situation regulations, written consent must be obtained by a doctor or an 
appropriately trained nurse from the participant (if capacity has been recovered) or Personal Legal 
Representative as soon as it is practicable to do so. 
 
A Personal Legal Representative may be a partner, friend or relative. 
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The participant’s decision to withdraw from the sub-study would overrule any decision made by a doctor or 
Personal Legal Representative.  
 
Sampling requirements 
 
Sub-study participants will give two blood samples and a nasal swab for sub-study purposes.  All samples 
will be obtained by an appropriately trained doctor or nurse. 
 
Table 1 provides a summary of the samples required.  
 
Table 1: Sub-study samp le requirement s 
 
Time point Sample  Details 
Baseline 
(after recruitment into ASAP 
trial and before, or within 4 
hours of 1st dose of ASAP 
study medication) 
16 ml peripheral blood  2 x 2.5 PAXgene tubes (RNA expression 
analysis) 
1 x 6ml plasma gel tube (corticosteroid 
pharmacokinetics) 
1 x 5ml serum gel tube (multiplex cytokine 
array)  
Nasal swab Collected in standard viral transport medium. 
This sample will be in addition to any nasal 
swab taken for clinical purposes, but may be 
taken at the same time-point if appropriate. 
Mid-treatment 
(48 hours (+/- 3 hours) after 
1st dose of study medication, 
or prior to hospital discharge, 
whichever is sooner) 
20 ml peripheral blood 1 x 5ml plasma gel tube (corticosteroid 
pharmacokinetics) 
1 x 5ml serum gel tube (multiplex cytokine 
array) 
1 x 10ml EDTA tube (genotyping) 
 
Sample collection, storage and transport 
 
Blood samples 
A 16ml peripheral blood sample must be obtained before or within 4 hours of the first dose of ASAP study 
medication being given to the participant. Blood will be collected into 3 different tube types as outlined in 
Table 1. Of note, the PAXgene tubes should be collected last and should be used along with an extension 
adapter. Use of the adapter reduces the risk of reflux of the PAXgene preservative liquid during the blood 
draw. 
 
A second 20ml peripheral blood sample must be obtained mid-treatment (at 48 hours (+/- 3 hours) after 
the first dose of ASAP study medication, or prior to hospital discharge, whichever is sooner).  
 
Blood samples will be labelled with a unique sample identifier which will encode the study, participant trial 
ID number and the sample type and time point. All blood samples will be sent to the clinical laboratories at 
the hospital where the participant has been recruited. PAXgene tubes must stand at room temperature 
(RT) for at least 3 hours and no longer than 72 hours. They are then transferred to a standard -21°C 
freezer then when frozen racked and transferred to a -80°C freezer. The initial RT phase enables the RNA 
stabilisation solution to penetrate cells. The -21°C freeze prevents the glass bottle cracking when taken 
down to -80°C. Serum gel and plasma gel tubes will be labelled with similar unique identifiers. They 
should be spun and separated into 500uL aliquots which should be labelled, racked and frozen at -80°C. 
 
All blood samples should be retained at site until recruitment to the sub-study has been completed. Frozen 
blood samples should then be sent by courier, on dry ice in a single batch to the Liverpool School of 
Tropical Medicine (LSTM) where they will be stored at -80°C until analysed. A Material Transfer 
Agreement (MTA) will be established between recruiting sites and LSTM to facilitate this. 
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Nasal swabs 
A nasal swab must be taken on enrolment.  Standard virus swabs with associated virological media will be 
used and provided in study packs to participating sites by the coordinating centre in Liverpool.  All swabs 
will be promptly labelled and frozen to -80°C.  All swabs will subsequently be transferred on dry ice to the 
Department of Virology, Royal Liverpool University Hospital where then will stored until analysis is 
performed. 
 
Equipment for sampling 
All materials related to the mechanistic sub study samples will be purchased by, and packs created in, 
Liverpool. These study packs will then be sent out to the sub-study sites. 
 
Sample analysis 
 
Blood samples 
Once blood samples are received at the Liverpool School of Tropical Medicine, HTA compliant storage 
and archiving (Procuro system used for laboratory information) of blood samples will be provided in the 
Liverpool School of Tropical Medicine Respiratory Infection group.  
 
Analysis of samples will be performed in a single batch using either RNA microarray expression analysis 
or next generation sequencing, depending on which is the most cost-effective method to obtain the data 
needed at the time analysis is carried out. This is a fast-moving technology and while the current balance 
would still favour microarray, it is anticipated that this will no longer be the case in a few years. 
 
An inflammatory array of genes expressed during acute influenza (+/- steroids) will be described (using 
microarray or sequencing technology). These data will inform the clinical severity score, the duration of 
illness and most importantly will confirm the immune-modulatory effect of steroids 
 
Nasal swabs 
The latest test available to detect influenza virus including the pandemic strain will be used; this is 
expected to be a PCR test, however the specific test cannot be determined until the point of trial 
activation. After testing, all nasal swabs will be disposed of. 
 
Surplus samples 
Consent will be sought from sub-study participants for any remaining samples to be stored and used for 
future ethically approved research. Where consent has been given remaining samples will be stored in 
under a storage license from the Human Tissue Authority (HTA). Request for access to these samples for 
future ethically approved research will be made through the Chief Investigator and lead sub-study 
Investigator. Any outputs arising from use of these samples must reflect the contributions of both study 
teams. 
 
Data collection 
No additional data over and above that collection for the ASAP trial is required for the sub-study. 
 
Withdrawal 
Each sub-study participant has the right to withdraw from the sub-study at any time. In addition, the 
investigator may withdraw a participant from the sub-study at any time if the investigator considers it 
necessary for any reason. Any samples already collected for the sub-study would still be used unless 
specifically requested not to, in which case any samples collected would be destroyed. 
 
The reason for withdrawal from the sub-study will be requested and recorded in the trial database, 
however participants are not obliged to give reasons.  
 
There will be no replacement of participants who withdraw from the sub-study. 
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Statistical analyses 
Data arising from the sub-study will be analysed by sub-study investigators at the Liverpool School of 
Tropical Medicine and University Hospital Aintree. 
 
The following assumes that the platform chosen to achieve the stated aims is microarray analysis of the 
whole blood RNA transcriptome between subjects (placebo vs control) normalised to the transciptome of a 
set of healthy volunteers.  
 
All analyses will be conducted in the latest version of R (currently 3.1.0).  For analysis of the RNA 
transcriptome data we will use the latest version of the package Bioconductor (currently version 2.14).  An 
initial normalisation step will be carried out to account for technical variation in the gene expression data 
between samples.  Differential gene expression analysis will be explored between treatment and control 
samples using the normalised expression data.   
 
 To address aim one, using day zero data, levels of expression of genes that defined temporal 
stage in the paper by  Huang et al. will be summarised using appropriate descriptive statistics in 
order to define when in the course of flu infection patients were recruited to the study.  
 
 To address aim two comparing steroid with placebo groups, between-group differences in the 
expression of relevant genes on day 3 will be estimated using appropriate regression models 4.   
 
 To address aim three - functional analysis of genes of interest (those that are differentially 
expressed between treatment and placebo groups) will be performed to infer the mechanism of 
action of steroid when given to patients with pandemic influenza; this will be a descriptive 
analysis.  
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Appendix 2 Consent form
Parcipant ID number when allocated:                                                     NHS or Hospital No. ____________________ 
 
ASAP PIS and consent form version 1.0 11-Feb-2014                                                                                                             Page  of  
Patient Information Sheet and Consent 
 
The ASAP (Steroids in Adults with Pandemic Influenza) Trial 
 
 
Does taking a steroid help improve recovery from pandemic flu? 
You have been admitted to hospital with influenza-like illness and need urgent care. You will get all the 
usual treatment for influenza-like illness that we provide at this hospital. As well as this, we would like to 
include you in a research study to see if a steroid called dexamethasone helps patients hospitalised with 
pandemic flu. Some studies have shown that this drug improves the outcome in patients with pneumonia 
or severe ‘blood poisoning’. We do not know if this drug will help with pandemic flu so we are doing this 
study.  
 
If you agree to take part in the study you will be given study medicine to take for 5 days. This is a 
liquid and you will take 15ml (about 3 teaspoons) orally once a day. If your standard treatment needs to 
be given via a feeding tube then the study medicine will also be given to you via the feeding tube. The 
study medicine will be given in addition to the normal treatment given to patients with flu.  
 
The study medicine will contain either dexamethasone or placebo. Placebo is a dummy medicine 
containing no active ingredients. Which treatment you receive is determined by chance (i.e. at random). 
Neither you nor any of the doctors or nurses looking after you will know which treatment you are 
receiving. Using a placebo helps us to make a fair test between treatments. 
 
Steroids such as dexamethasone are very commonly used drugs. When given for a short time, as in 
this study, steroids are generally considered safe with few side-effects. If the doctor looking after you 
feels you should not receive steroids, you will not be eligible to take part in this study. 
 
We will need to collect some information from your medical notes about your stay in hospital and will 
send this to a central office in Nottingham. We will also send them your contact details and your NHS 
number so that they can find out how you are doing after you have left hospital and send you a short 5 
minute questionnaire to complete one month after you go home from hospital. If you agree to participate 
in the study your GP will also be informed. 
 
If you want to know more about our study now then we will tell you. But otherwise we will give you an 
information leaflet to read at a later time which tells you everything you need to know. You do not have to 
take part and you may change your mind at any time; please just tell your doctor or nurse.  
 
This study has been approved by the South Central – Oxford C Research Ethics Committee (REC). 
 
 
 
I confirm that I have been given a copy of the Patient Information Leaflet (version 2.0, dated 11-Feb-
2014) and I agree to participate in the ASAP study; for my medical records to be accessed, my GP 
informed and my contact details and NHS number collected and used for the purpose of the study.  
 
 
 
 
 
     
Name of participant 
 
 
 
 
 Signature  Date 
Name of person taking consent  Signature  Date 
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 Parcipant ID number when allocated:                                                     NHS or Hospital No. ____________________ 
 
ASAP PLR info sheet and consent form version 1.0 11-Feb-2014                                                                                                                                Page 1 of 1 
Personal Legal Representative* Information Sheet & Consent
*May be a partner, relative or friend 
 
The ASAP (Steroids in Adults with Pandemic Influenza) Trial 
 
 
Does taking a steroid help improve recovery from pandemic flu? 
Your partner/relative/friend has been admitted to hospital with influenza-like illness and needs urgent 
care. They will get all the usual treatment for influenza-like illness that we provide at this hospital. As well 
as this, we would like to include them in a research study to see if a steroid called dexamethasone helps 
patients hospitalised with pandemic flu. Some studies have shown that this drug improves the outcome 
in patients with pneumonia or severe ‘blood poisoning’. We do not know if this drug will help with 
pandemic flu so we are doing this study.  
 
If you agree for your partner/relative/friend to take part in the study they will be given study 
medicine to take for 5 days. This is a liquid and they will take 15ml (about 3 teaspoons) orally once a 
day. If their standard treatment needs to be given via a feeding tube then the study medicine will also be 
given to them via the feeding tube. The study medicine will be given in addition to the normal treatment 
given to patients with flu.  
 
The study medicine will contain either dexamethasone or placebo. Placebo is a dummy medicine 
containing no active ingredients. Which treatment they receive is determined by chance (i.e.at random). 
Neither you nor any of the doctors or nurses looking after them will know which treatment they are 
receiving. Using a placebo helps us to make a fair test between treatments. 
 
Steroids such as dexamethasone are very commonly used drugs. When given for a short time, as in 
this study, steroids are generally considered safe with few side-effects. If the doctor looking after your 
partner/relative/friend feels they should not receive steroids, they will not be eligible to take part in this 
study. 
 
We will need to collect some information from your partner/relative/friend’s medical notes about their 
stay in hospital and will send this to a central office in Nottingham. We will also send their contact details 
(we may also send your contact details as well) and NHS number so that they can find out how your 
partner/relative/friend is doing after they leave hospital and a send a short 5 minute questionnaire to 
complete one month after they go home from hospital. We will also inform their GP. 
 
If you want to know more about our study now then we will tell you. But otherwise we will give you an 
information leaflet to read at a later time which tells you everything you need to know. Your 
partner/relative/friend does not have to take part and you/they may change your/their mind at any time; 
please tell their doctor or nurse if there is a change of mind.  
 
This study has been approved by the South Central – Oxford C Research Ethics Committee (REC). 
 
I confirm that I have been given a copy of the Personal Legal Representative Information Leaflet (version 
2.0, dated 11-Feb-2014) and I agree for them to participate in the ASAP study; for their medical records 
to be accessed, their GP informed and contact details and NHS number collected and used for the 
purpose of the study.  
 
 
 
 
 Relationship to participant: _______________ Name of participant: ______________________________ 
    
 
Name of person taking consent  Signature  Date 
 
Name of person giving consent  Signature  Date 
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h
e
ir
 b
e
s
t
 t
o
 a
n
s
w
e
r
 y
o
u
r
 q
u
o
r
 y
o
u
 
c
a
n
 
c
o
n
t
a
c
t
 
t
h
e
 
 
A
d
v
ic
e
 
a
n
d
 
L
ia
is
o
n
 
S
e
r
v
ic
e
 
(
P
A
L
S
);
 c
o
n
t
a
c
t
 d
e
t
a
il
s
 c
a
n
 b
e
 f
o
u
n
d
 o
n
 t
h
e
 b
a
c
k
 o
f
 t
h
is
 
le
a
ﬂ
e
t
 
 If
 y
o
u
 r
e
m
a
in
 u
n
h
a
p
p
y
 a
n
d
 w
is
h
 t
o
 c
o
m
p
la
in
 f
o
r
m
a
ll
y
, 
y
o
u
 
c
a
n
 
d
o
 
t
h
is
 
t
h
r
o
u
g
h
 
t
h
e
 
N
H
S
 
C
o
m
p
la
in
t
s
  
  
  
  
  
  
 
P
r
o
c
e
d
u
r
e
. 
D
e
t
a
il
s
 c
a
n
 b
e
 o
b
t
a
in
e
d
 f
r
o
m
 y
o
u
r
 h
o
s
p
it
a
l.
 
 In
 
t
h
e
 
e
v
e
n
t
 
t
h
a
t
 
s
o
m
e
t
h
in
g
 
d
o
e
s
 
g
o
 
w
r
o
n
g
 
a
n
d
 
y
o
u
 
a
r
e
 
h
a
r
m
e
d
 
d
u
r
in
g
 
t
h
e
 
s
t
u
d
y
 
t
h
e
r
e
 
a
r
e
 
n
o
 
s
p
e
c
ia
l 
 
o
n
 
a
r
r
a
n
g
e
m
e
n
t
s
. 
If
 
y
o
u
 
a
r
e
 
h
a
r
m
e
d
 
a
n
d
 
t
h
is
 
is
 
d
u
e
 
t
o
 
s
o
m
e
o
n
e
’s
 
n
e
g
li
g
e
n
c
e
 
t
h
e
n
 
y
o
u
 
m
a
y
 
h
a
v
e
 
g
r
o
u
n
d
s
 
fo
r
 
le
g
a
l 
a
c
fo
r
 
c
o
o
n
 
b
u
t
 
y
o
u
 
m
a
y
 
h
a
v
e
 
t
o
 
p
a
y
 
y
o
u
r
 
le
g
a
l 
c
o
s
t
s
. 
T
h
e
 
n
o
r
m
a
l 
  
  
H
e
a
lt
h
 
S
e
r
v
ic
e
 
c
o
m
p
la
in
t
s
 
m
e
c
h
a
n
is
m
s
 
w
il
l 
 
Th
e 
A
SA
P 
tr
ia
l i
s 
fu
nd
ed
 b
y 
th
e 
N
at
io
na
l I
ns
tit
ut
e 
fo
r  
   
   
   
   
  
H
ea
lth
 R
es
ea
rc
h 
(N
IH
R
 ) 
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A
t
 t
h
e
 e
n
d
 o
f 
t
h
e
 s
t
u
d
y
, 
w
e
 w
il
l 
b
e
 a
b
le
 t
o
 c
o
m
p
a
r
e
 i
f 
w
h
o
 
t
o
o
k
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
d
id
 
b
  
  
  
 
e
n
t
s
 w
h
o
 t
o
o
k
 p
la
c
e
b
o
. 
 In
 a
ll 
in
st
an
ce
s,
 y
ou
 w
ill
 s
re
ce
iv
e 
th
e 
st
an
da
rd
 
tr
ea
tm
en
t 
cu
rr
en
tly
 u
se
d 
to
 t
re
at
 p
 w
it
h 
a 
 
flu
-li
ke
  i
lln
es
s.
 
o 
ho
sp
it
al
 w
it
h 
flu
? 
 
W
e 
w
ou
ld
 li
ke
 to
 in
vi
te
 y
ou
 to
 ta
ke
 p
ar
t i
n 
ou
r  
  
re
se
ar
ch
 s
tu
dy
.  
W
ha
t i
s 
th
e 
pu
rp
os
e 
of
 th
e 
st
ud
y?
 
 
S
o
m
e
 s
t
u
d
ie
s
 h
a
v
e
 s
h
o
w
n
 t
h
a
t
 a
 s
t
e
r
o
id
 d
r
u
g
 c
a
ll
e
d
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
im
p
r
o
v
e
s
 
t
h
e
 
o
u
t
c
o
m
e
 
in
 
p
e
n
t
s
 
w
it
h
 p
n
e
u
m
o
n
ia
 o
r
 s
e
v
e
r
e
 ‘
b
lo
o
d
 p
o
is
o
n
in
g
’.
 T
h
e
r
e
 
is
 u
n
c
e
r
t
a
in
t
y
 w
h
e
t
h
e
r
 t
h
is
 d
r
u
g
 m
ig
h
t
 a
ls
o
 i
m
p
r
o
v
e
 
t
h
e
 
r
e
c
o
v
e
r
y
 
o
f 
w
it
h
 
s
e
v
e
r
e
 
ﬂ
u
 
i
  
In
 
t
h
is
 
s
t
u
d
y
 
w
e
 
a
r
e
 
t
r
y
in
g
 
t
o
 
ﬁ
n
d
 
o
u
t
 
w
h
e
t
h
e
r
  
  
  
  
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
g
iv
e
n
 
f
o
r
 5
 
d
a
y
s
 
in
 
t
o
 
t
h
e
 
n
o
r
m
a
l 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
ﬂ
u
 
is
 
b
e
n
e
ﬁ
c
ia
l 
in
 
h
o
s
p
it
a
l 
w
it
h
 ﬂ
u
 d
u
r
in
g
 a
 p
a
n
d
e
m
ic
. 
 W
e 
ar
e 
as
ki
ng
 u
p 
to
 2
20
0 
p
 a
 t
o 
  
ho
sp
it
al
 w
it
h 
a 
flu
-li
ke
 il
ln
es
s 
to
 t
ak
e 
pa
rt
. 
Po
ss
ib
le
 d
is
ad
va
nt
ag
es
/r
is
ks
 
 
S
t
e
r
o
id
s
 a
r
e
 v
e
r
y
 c
o
m
m
o
n
ly
 u
s
e
d
 d
r
u
g
s
. 
 S
id
e
 e
ﬀ
e
c
t
s
 
c
a
n
 
in
c
lu
d
e
 
in
c
r
e
a
s
e
d
 
, 
a
c
n
e
, 
m
o
o
d
 
c
h
a
n
g
e
s
 
s
u
c
h
 a
s
 b
e
c
o
m
in
g
 v
e
r
y
 a
g
g
r
e
s
s
iv
e
, 
ir
r
it
a
b
le
 a
n
d
 s
h
o
r
t
 
t
e
m
p
e
r
e
d
 
w
it
h
 
p
e
o
p
le
 
a
n
d
 
r
a
p
id
 
m
o
o
d
 
s
w
in
g
s
, 
s
u
c
h
 
a
s
 f
e
e
li
n
g
 v
e
r
y
 h
a
p
p
y
 o
n
e
 m
in
u
t
e
 a
n
d
 s
a
d
 a
n
d
 w
e
e
p
y
  
t
h
e
 
n
e
x
t
. 
T
h
e
s
e
 
a
r
e
 
v
e
r
y
 
r
a
r
e
. 
s
t
u
d
ie
s
 
(
t
r
ia
ls
)
 o
f
 s
t
e
r
o
id
s
 i
n
 p
n
e
u
m
o
n
ia
 a
n
d
 b
lo
o
d
 p
o
is
o
n
in
g
 
h
a
v
e
 
s
h
o
w
n
 
im
p
r
o
v
e
d
 
o
u
t
c
o
m
e
s
 
w
it
h
 
s
t
e
r
o
id
s
 
le
s
s
 
li
k
e
ly
 
t
o
 
d
ie
 
a
n
d
 
r
e
d
u
c
e
d
 
le
n
g
t
h
 
o
f 
  
 
h
o
s
p
it
a
l 
s
t
a
y
) 
w
it
h
o
u
t
 
a
n
y
 
a
s
s
o
c
ia
t
e
d
 
m
a
jo
r
 
h
a
r
m
f
u
l 
e
ﬀ
e
c
t
s
. 
L
e
s
s
 
r
e
li
a
b
le
 
s
t
u
d
ie
s
 
c
o
n
d
u
c
t
e
d
 
d
u
r
in
g
 
t
h
e
 
2
0
0
9
 
p
a
n
d
e
m
ic
 
h
a
v
e
 
s
h
o
w
n
 
m
ix
e
d
 
r
e
s
u
lt
s
—
in
 
s
o
m
e
 
s
t
u
d
ie
s
 
w
h
o
 
r
e
c
e
iv
e
d
 
s
t
e
r
o
id
s
 
w
e
r
e
 
m
o
r
e
 
li
k
e
ly
 
t
o
 
d
ie
 
a
n
d
 
in
 
o
t
h
e
r
 
s
t
u
d
ie
s
 
w
e
r
e
 
n
o
 
m
o
r
e
 l
ik
e
ly
 t
o
 d
ie
, 
c
o
m
p
a
r
e
d
 t
o
 p
w
h
o
 d
id
 n
o
t
 
r
e
c
e
iv
e
 s
t
e
r
o
id
s
. 
A
bo
ut
 th
e 
st
ud
y 
m
ed
ic
in
e 
 
T
h
e
 
s
t
u
d
y
 
m
e
d
ic
in
e
 
is
 
a
 
li
q
u
id
. 
Y
o
u
 
w
il
l 
b
e
 
g
iv
e
n
 
a
 
c
o
n
t
a
in
in
g
 e
n
o
u
g
h
  
m
e
d
ic
in
e
 t
o
 l
a
s
t
 f
o
r
 5
 d
a
y
s
. 
Y
o
u
 w
il
l 
n
e
e
d
 t
o
 t
a
k
e
 1
5
m
l 
b
y
 m
o
u
t
h
 o
n
c
e
 a
 d
a
y
 f
o
r
 5
 
d
a
y
s
. 
If
 
y
o
u
 
a
r
e
 
t
o
o
 
p
o
o
r
ly
 
t
o
 
t
a
k
e
 
y
o
u
r
 
s
t
a
n
d
a
r
d
 
t
r
e
a
t
m
e
n
t
 b
y
 m
o
u
t
h
, 
d
o
c
t
o
r
s
 m
a
y
 u
s
e
 a
 f
e
e
d
in
g
 t
u
b
e
 
t
o
 g
iv
e
 y
o
u
 t
r
e
a
t
m
e
n
t
 d
ir
e
c
t
ly
 t
o
 y
o
u
r
 s
t
o
m
a
c
h
. 
If
 t
h
is
  
  
  
h
a
p
p
e
n
s
, 
t
h
e
 
f
e
e
d
in
g
 
t
u
b
e
 
w
il
l 
a
ls
o
 
b
e
 
u
s
e
d
 
t
o
 
g
iv
e
 
t
h
e
 s
t
u
d
y
 m
e
d
ic
in
e
. 
 Y
o
u
r
 
d
o
c
t
o
r
 
w
il
l 
e
x
p
la
in
 
h
o
w
 
t
o
 
t
a
k
e
 
y
o
u
r
 
m
e
d
ic
in
e
 
a
n
d
 
y
o
u
 
n
e
e
d
 
t
o
 
d
o
 
t
h
is
 
fo
r
 
5
 
d
a
y
s
. 
If
 
y
o
u
 
le
a
v
e
  
  
  
h
o
s
p
it
a
l 
t
h
e
n
 
y
o
u
 
w
il
l 
t
a
k
e
 
t
h
e
 
m
e
d
ic
in
e
 
h
o
m
e
 
t
o
 
it
 
a
t
 
h
o
m
e
. 
Y
o
u
 
s
h
o
u
ld
 
c
o
t
o
 
t
a
k
e
 
y
o
u
r
 m
e
d
ic
in
e
 a
s
 y
o
u
r
 d
o
c
t
o
r
 t
e
ll
s
 y
o
u
 t
o
. 
Po
ss
ib
le
 b
en
efi
ts
 
 
W
e
 c
a
n
n
o
t
 p
r
o
m
is
e
 t
h
a
t
 t
h
e
 s
t
u
d
y
 w
il
l 
h
e
lp
 y
o
u
, 
b
u
t
 
t
h
e
 
in
f
o
r
m
t
h
a
t
 
w
e
 
g
e
t
 
f
r
o
m
 
t
h
e
 
s
t
u
d
y
 
m
ig
h
t
 
h
e
lp
 
im
p
r
o
v
e
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
p
w
it
h
  
  
  
 
p
a
n
d
e
m
ic
 ﬂ
u
 i
n
 t
h
e
 f
u
t
u
r
e
. 
? 
 
W
e
 
w
a
n
t
 
t
o
 
lo
o
k
 
in
 
y
o
u
r
 
m
e
d
ic
a
l 
n
o
t
e
s
 
fo
r
  
  
  
  
  
  
  
o
n
 
a
b
o
u
t
 
y
o
u
r
 
il
ln
e
s
s
 
a
n
d
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
y
o
u
r
 d
o
c
t
o
r
 
g
iv
e
s
 y
o
u
 w
h
il
s
t
 i
n
 h
o
s
p
it
a
l.
 Y
o
u
r
 d
o
c
t
o
r
 
w
il
l 
g
iv
e
 t
h
is
 t
o
 u
s
 w
it
h
 y
o
u
r
 p
e
r
m
is
s
io
n
. 
 W
e
 
w
o
u
ld
 
li
k
e
 
t
o
 
ﬁ
n
d
 
o
u
t
 
h
o
w
 
y
o
u
 
a
r
e
 
d
o
in
g
 
o
n
e
 
m
o
n
t
h
 
e
r
 
y
o
u
 
le
a
v
e
 
h
o
s
p
it
a
l.
 
W
e
 
w
il
l 
s
e
n
d
 
y
o
u
 
a
 
s
h
o
r
t
 q
u
t
h
is
 w
il
l 
t
a
k
e
 a
b
o
u
t
 5
 m
in
u
t
e
s
 t
o
 
c
o
m
p
le
t
e
. 
T
h
e
 
w
il
l 
b
e
 p
o
s
t
e
d
 t
o
 y
o
u
 a
t
 
y
o
u
r
 
h
o
m
e
, 
w
it
h
 
a
 
f
r
e
e
p
o
s
t
 
r
e
t
u
r
n
 
e
n
v
e
lo
p
e
. 
Y
o
u
r
 
c
o
n
t
a
c
t
 
d
e
t
a
il
s
 
w
il
l 
b
e
 
c
o
ll
e
c
t
e
d
 
a
n
d
 
s
e
n
t
 
t
o
 
t
h
e
  
  
  
 
C
e
n
t
r
e
 
in
 
fo
r
 
t
h
is
 
p
u
r
p
o
s
e
. 
If
 
w
e
 
d
o
 
n
o
t
 
h
e
a
r
 
f
r
o
m
 
y
o
u
 
a
a
 
w
e
 
w
il
l 
 
t
o
 
c
o
n
t
a
c
t
 
y
o
u
 
b
y
 
t
e
le
p
h
o
n
e
 
t
o
 
ﬁ
n
d
 
o
u
t
 
if
 
y
o
u
 
h
a
v
e
 
r
e
c
e
iv
e
d
 
t
h
e
 
q
u
a
n
d
 
h
o
w
 
y
o
u
 
a
r
e
 d
o
in
g
. 
W
ha
t w
ill
 I 
ha
ve
 to
 d
o?
 
 
If
 
y
o
u
 
d
e
c
id
e
 
t
o
 t
a
k
e
 
p
a
r
t
 
in
 
t
h
e
 
s
t
u
d
y
 
y
o
u
 
w
il
l 
b
e
  
g
iv
e
n
 s
o
m
e
 s
t
u
d
y
 m
e
d
ic
in
e
 t
o
 t
a
k
e
 o
n
c
e
 a
 d
a
y
 f
o
r
 
5
 d
a
y
s
. 
 T
h
e
 s
t
u
d
y
 m
e
d
ic
in
e
 w
il
l 
c
o
n
t
a
in
 e
it
h
e
r
: 
1
) 
d
e
x
a
m
e
t
h
a
s
o
n
e
 o
r
  
2)
 
a
 
p
la
c
e
b
o
 
(
a
 
d
u
m
m
y
 
t
r
e
a
t
m
e
n
t
 w
h
ic
h
 
lo
o
k
s
 
li
k
e
 t
h
e
 r
e
a
l 
m
e
d
ic
in
e
 b
u
t
 c
o
n
t
a
in
s
 n
o
 
v
e
 
in
g
r
e
d
ie
n
t
.)
  
 U
s
in
g
 
a
 
p
la
c
e
b
o
 
h
e
lp
s
 
u
s
 
m
a
k
e
 
a
 
f
a
ir
 
c
o
m
p
a
r
is
o
n
 
o
f
 
t
h
e
 
 
t
r
e
a
t
m
e
n
t
s
. 
N
e
it
h
e
r
 
y
o
u
 
n
o
r
 
a
n
y
 
o
f 
t
h
e
  
d
o
c
t
o
r
s
 
o
r
 
n
u
r
s
e
s
 
lo
o
k
in
g
 
y
o
u
 
w
il
l 
k
n
o
w
 
w
h
ic
h
 
t
r
e
a
t
m
e
n
t
 
y
o
u
 
a
r
e
 
r
e
c
e
iv
in
g
 
(
a
lt
h
o
u
g
h
 
if
 
t
h
e
y
 n
e
e
d
 t
o
 ﬁ
n
d
 o
u
t
 t
h
e
y
 c
a
n
 d
o
 s
o
)
. 
T
h
e
 d
e
c
is
io
n
 
a
b
o
u
t
 w
h
ic
h
 t
r
e
a
t
m
e
n
t
 y
o
u
 r
e
c
e
iv
e
 w
il
l 
b
e
 d
e
c
id
e
d
 
b
y
 
c
h
a
n
c
e
 
(
r
a
t
h
e
r
 
li
k
e
 
t
o
s
s
in
g
 
a
 
c
o
in
)
 
a
n
d
 
n
e
it
h
e
r
 
y
o
u
 n
o
r
 y
o
u
r
 d
o
c
t
o
r
 w
il
l 
b
e
 a
b
le
 t
o
 c
h
o
o
s
e
. 
T
h
is
 i
s
 
im
p
o
r
t
a
n
t
 a
s
 i
t
 e
n
s
u
r
e
s
 a
 f
a
ir
 c
o
m
p
a
r
is
o
n
 b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
s
. 
 
 
 
W
h
e
n
 y
o
u
 h
a
v
e
 ﬁ
n
is
h
e
d
 y
o
u
r
 s
t
u
d
y
 m
e
d
ic
in
e
 y
o
u
 w
il
l 
r
e
c
e
iv
e
 n
o
r
m
a
l 
c
a
r
e
 w
h
il
s
t
 i
n
 h
o
s
p
it
a
l.
 I
f 
y
o
u
 h
a
v
e
 l
e
h
o
s
p
it
a
l 
a
t
 
t
h
is
 
p
o
in
t
 
y
o
u
 
w
il
l 
n
o
t
 
h
a
v
e
 
t
o
 
d
o
  
  
  
  
a
n
y
t
h
in
g
. 
W
e
 
w
il
l 
c
o
n
t
a
c
t
 
y
o
u
 
w
it
h
 
a
 
o
n
e
 m
o
. 
Re
su
lt
s 
of
 th
e 
st
ud
y 
 
T
h
e
 
r
e
s
u
lt
s
 
o
f
 
t
h
e
 
s
t
u
d
y
 
w
il
l 
b
e
 
a
v
a
il
a
b
le
 
it
 
h
a
s
 
ﬁ
n
is
h
e
d
 
a
n
d
 
w
il
l 
u
s
u
a
ll
y
 
b
e
 
p
u
b
li
s
h
e
d
 
in
 
a
 
ﬁ
c
 
jo
u
r
n
a
l 
a
n
d
 
b
e
 
p
r
e
s
e
n
t
e
d
 
a
t
 
a
 
 
c
o
n
f
e
r
e
n
c
e
. 
H
o
w
e
v
e
r
, 
y
o
u
 
w
il
l 
n
o
t
 
b
e
 
i
in
 
a
n
y
 
r
e
p
o
r
t
 
o
r
 
 
A
 
s
u
m
m
a
r
y
 
o
f
 
t
h
e
 
r
e
s
u
lt
s
 
w
il
l 
a
ls
o
 
b
e
 
s
e
n
t
 t
o
  
y
o
u
. 
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at
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yo
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 m
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fo
rm
at
io
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an
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er
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st
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W
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 re
vi
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ed
 th
e 
st
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y?
 
 
A
ll
 
r
e
s
e
a
r
c
h
 
in
 
t
h
e
 
N
H
S
 
is
 
lo
o
k
e
d
 
a
t
 
b
y
 
a
n
  
  
  
  
  
  
  
  
in
d
e
p
e
n
d
e
n
t
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r
o
u
p
 o
f 
p
e
o
p
le
 c
a
ll
e
d
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 R
e
s
e
a
r
c
h
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t
h
ic
s
 
C
o
m
m
i
e
, 
t
o
 
p
r
o
t
e
c
t
 
y
o
u
r
 
s
a
f
e
t
y
, 
r
ig
h
t
s
, 
w
e
ll
b
e
in
g
 
a
n
d
 
d
ig
n
it
y
. 
T
h
is
 
s
t
u
d
y
 
h
a
s
 
b
e
e
n
 
r
e
v
ie
w
e
d
 
b
y
 
t
h
e
 
S
o
u
t
h
 C
e
n
t
r
a
l—
.  
W
ha
t i
f t
he
re
 is
 a
 p
ro
bl
em
? 
 
If
 y
o
u
 h
a
v
e
 a
 c
o
n
c
e
r
n
 o
r
 q
u
a
b
o
u
t
 a
n
y
 a
s
p
e
c
t
 o
f
 
t
h
is
 
s
t
u
d
y
 
y
o
u
 
s
h
o
u
ld
 
s
p
e
a
k
 
t
o
 
t
h
e
 
lo
c
a
l 
s
t
u
d
y
 
t
e
a
m
 
w
h
o
 w
il
l 
d
o
 t
h
e
ir
 b
e
s
t
 t
o
 a
n
s
w
e
r
 y
o
u
r
 q
u
o
r
 y
o
u
 
c
a
n
 
c
o
n
t
a
c
t
 
t
h
e
 
A
d
v
ic
e
 
&
 
L
ia
is
o
n
 
S
e
r
v
ic
e
 
(
P
A
L
S
);
 c
o
n
t
a
c
t
 d
e
t
a
il
s
 a
r
e
 o
n
 t
h
e
 b
a
c
k
 o
f
 t
h
is
 l
e
a
ﬂ
e
t.
 
 If
 y
o
u
 r
e
m
a
in
 u
n
h
a
p
p
y
 a
n
d
 w
is
h
 t
o
 c
o
m
p
la
in
 f
o
r
m
a
ll
y
, 
y
o
u
 
c
a
n
 
d
o
 
t
h
is
 
t
h
r
o
u
g
h
 
t
h
e
 
N
H
S
 
C
o
m
p
la
in
t
s
  
  
  
  
  
  
 
P
r
o
c
e
d
u
r
e
. 
D
e
t
a
il
s
 c
a
n
 b
e
 o
b
t
a
in
e
d
 f
r
o
m
 y
o
u
r
 h
o
s
p
it
a
l.
 
 In
 
t
h
e
 
e
v
e
n
t
 
t
h
a
t
 
s
o
m
e
t
h
in
g
 
d
o
e
s
 
g
o
 
w
r
o
n
g
 
a
n
d
 
y
o
u
r
 
p
a
r
t
n
e
r
/
f
r
i
v
e
 
is
 
h
a
r
m
e
d
 
d
u
r
in
g
 
t
h
e
 
s
t
u
d
y
 
t
h
e
r
e
 
a
r
e
 
n
o
 
s
p
e
c
ia
l 
o
n
 
a
r
r
a
n
g
e
m
e
n
t
s
. 
If
 
y
o
u
r
 
v
e
/
f
r
ie
n
d
 
is
 
h
a
r
m
e
d
 
a
n
d
 
t
h
is
 
is
 
d
u
e
 
t
o
 
s
o
m
e
o
n
e
’s
 
n
e
g
li
g
e
n
c
e
 
t
h
e
n
 
y
o
u
 
m
a
y
 
h
a
v
e
 
g
r
o
u
n
d
s
 
f
o
r
 l
e
g
a
l 
a
n
 f
o
r
 c
o
m
p
e
n
b
u
t
 y
o
u
 m
a
y
 h
a
v
e
 t
o
 
p
a
y
 
y
o
u
r
 
le
g
a
l 
c
o
s
t
s
. 
T
h
e
 
n
o
r
m
a
l 
H
e
a
lt
h
  
  
 
S
e
r
v
ic
e
 c
o
m
p
la
in
t
s
 m
e
c
h
a
n
b
e
 a
v
a
il
a
b
le
 t
o
 
y
o
u
. W
ill
 m
y 
pa
rt
ne
r/
fr
ie
nd
/r
el
a
ki
ng
 p
ar
t b
e 
ke
pt
 c
on
fid
e
al
? 
 
A
ll
 
in
f
o
r
m
 
w
e
 
c
o
ll
e
c
t
 
a
b
o
u
t
 
y
o
u
r
 
p
a
r
t
n
e
r
/
w
il
l 
b
e
 
k
e
p
t
 
in
 
t
h
e
 
s
t
r
ic
t
e
s
t
  
  
  
  
  
  
 
c
o
n
ﬁ
d
e
n
c
e
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O
n
ly
 p
e
r
s
o
n
s
 i
n
v
o
lv
e
d
 i
n
 t
h
e
 c
o
n
d
u
c
t
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r
 
o
f
 
t
h
e
 
s
t
u
d
y
 
w
il
l 
h
a
v
e
 
a
c
c
e
s
s
 
t
o
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u
r
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a
r
t
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r
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r
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p
e
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o
n
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d
e
t
a
il
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W
e
 
w
il
l 
a
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o
 
r
e
g
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t
e
r
 
t
h
e
ir
 
N
H
S
 
n
u
m
b
e
r
 
w
it
h
 
t
h
e
 
H
e
a
lt
h
 
a
n
d
 
S
o
c
ia
l 
C
a
r
e
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f
o
r
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o
n
 
C
e
n
t
r
e
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h
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h
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h
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w
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u
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c
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c
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n
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t
a
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c
a
s
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e
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n
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c
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y
o
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t
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ﬁ
n
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u
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o
w
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h
e
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n
c
e
 
t
h
e
y
 
h
a
v
e
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h
o
s
p
it
a
l.
 
W
e
 
w
il
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h
a
v
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a
n
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s
e
c
u
r
it
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a
r
r
a
n
g
e
m
e
n
t
s
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n
 p
la
c
e
 t
o
 e
n
s
u
r
e
 a
ll
 d
e
t
a
il
s
 a
r
e
 d
e
a
lt
 
w
it
h
 i
n
 t
h
e
 s
t
r
ic
t
e
s
t
 c
o
n
ﬁ
d
e
n
c
e
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T
h
e
s
e
 d
e
t
a
il
s
 w
il
l 
b
e
 
k
e
p
t
 s
e
c
u
r
e
ly
, 
w
it
h
 a
c
c
e
s
s
  
 r
e
s
t
r
ic
t
e
d
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 Y
o
u
r
 p
a
r
t
n
e
r
/
w
il
l 
n
o
t
 
b
e
 
n
a
m
e
d
 
o
r
 
o
t
h
e
r
w
is
e
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e
 
w
il
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le
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o
u
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a
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t
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/
r
 
G
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k
n
o
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h
a
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h
e
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r
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k
in
g
 p
a
r
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h
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t
u
d
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 b
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ie
nd
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ia
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 b
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N
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c
o
m
p
a
r
is
o
n
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
s
. 
A
t
 
t
h
e
 
e
n
d
 
o
f
 
t
h
e
 
s
t
u
d
y
, 
w
e
 
w
il
l 
b
e
 
a
b
le
 
t
o
 
c
o
m
p
a
r
e
 
if
 
p
w
h
o
 
t
o
o
k
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
d
id
 
b
c
o
m
p
a
r
e
d
 
t
o
  
  
  
  
 
. 
 In
 a
ll 
in
st
an
ce
s,
 y
ou
r p
ar
tn
er
/r
e
e/
l 
re
ce
iv
e 
th
e 
st
an
da
rd
 t
re
at
m
en
t 
cu
rr
en
tly
 u
se
d 
to
 
-li
ke
  i
lln
es
s.
 
o 
ho
sp
it
al
 w
it
h 
flu
? 
 
W
e 
w
ou
ld
 lik
e 
to
 in
vi
te
 y
ou
r p
ar
tn
e
 
to
 ta
ke
 p
ar
t i
n 
ou
r r
es
ea
rc
h 
st
ud
y.
  
W
ha
t i
s 
th
e 
pu
rp
os
e 
of
 th
e 
st
ud
y?
 
 
S
o
m
e
 s
t
u
d
ie
s
 h
a
v
e
 s
h
o
w
n
 t
h
a
t
 a
 s
t
e
r
o
id
 d
r
u
g
 c
a
ll
e
d
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
im
p
r
o
v
e
s
 
t
h
e
 
o
u
t
c
o
m
e
 
in
 
p
e
n
t
s
 
w
it
h
 p
n
e
u
m
o
n
ia
 o
r
 s
e
v
e
r
e
 ‘
b
lo
o
d
 p
o
is
o
n
in
g
’.
 T
h
e
r
e
 
is
 u
n
c
e
r
t
a
in
t
y
 w
h
e
t
h
e
r
 t
h
is
 d
r
u
g
 m
ig
h
t
 a
ls
o
 i
m
p
r
o
v
e
 
t
h
e
 
r
e
c
o
v
e
r
y
 
o
f 
w
it
h
 
s
e
v
e
r
e
 
ﬂ
u
 
i
  
In
 
t
h
is
 
s
t
u
d
y
 
w
e
 
w
a
n
t
 
t
o
 
ﬁ
n
d
 
o
u
t
 
w
h
e
t
h
e
r
  
  
  
  
  
  
  
  
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
g
iv
e
n
 
f
o
r
 5
 
d
a
y
s
 
in
 
t
o
 
t
h
e
 
n
o
r
m
a
l 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
ﬂ
u
 
is
 
b
e
n
e
ﬁ
c
ia
l 
in
 
h
o
s
p
it
a
l 
w
it
h
 ﬂ
u
 d
u
r
in
g
 a
 p
a
n
d
e
m
ic
. 
 W
e 
ar
e 
as
ki
ng
 u
p 
to
 2
20
0 
p
 a
 t
o 
  
ho
sp
ita
l w
ith
 a
 fl
u
-li
ke
 il
ln
es
s 
to
 ta
ke
 p
ar
t.
 
Po
ss
ib
le
 d
is
ad
va
nt
ag
es
/r
is
ks
 
 
S
t
e
r
o
id
s
 a
r
e
 v
e
r
y
 c
o
m
m
o
n
ly
 u
s
e
d
 d
r
u
g
s
. 
 S
id
e
 e
ﬀ
e
c
t
s
 
c
a
n
 
in
c
lu
d
e
 
in
c
r
e
a
s
e
d
 
, 
a
c
n
e
, 
m
o
o
d
 
c
h
a
n
g
e
s
 
s
u
c
h
 a
s
 b
e
c
o
m
in
g
 v
e
r
y
 a
g
g
r
e
s
s
iv
e
, 
ir
r
it
a
b
le
 a
n
d
 s
h
o
r
t
 
t
e
m
p
e
r
e
d
 
w
it
h
 
p
e
o
p
le
 
a
n
d
 
r
a
p
id
 
m
o
o
d
 
s
w
in
g
s
, 
s
u
c
h
 
a
s
 
f
e
e
li
n
g
 
v
e
r
y
 
h
a
p
p
y
 
o
n
e
 
m
in
u
t
e
 
a
n
d
 
t
h
e
n
 
v
e
r
y
 
s
a
d
 
a
n
d
 
w
e
e
p
y
 
t
h
e
 
n
e
x
t
. 
T
h
e
s
e
 
a
r
e
 
v
e
r
y
 
r
a
r
e
. 
 
S
c
i
 
s
t
u
d
ie
s
 
(
t
r
ia
ls
) 
o
f 
s
t
e
r
o
id
s
 
in
 
p
n
e
u
m
o
n
ia
 
a
n
d
 
b
lo
o
d
 
p
o
is
o
n
in
g
 
h
a
v
e
 
s
h
o
w
n
 
im
p
r
o
v
e
d
 
o
u
t
c
o
m
e
s
 
w
it
h
  
s
t
e
r
o
id
s
 
 
le
s
s
 
li
k
e
ly
 
t
o
 
d
ie
 
a
n
d
 
r
e
d
u
c
e
d
 
le
n
g
t
h
 o
f
 h
o
s
p
it
a
l 
s
t
a
y
)
 w
it
h
o
u
t
 a
n
y
 a
s
s
o
c
ia
t
e
d
 m
a
jo
r
 
h
a
r
m
f
u
l 
e
ﬀ
e
c
t
s
. 
L
e
s
s
 
r
e
li
a
b
le
 
s
t
u
d
ie
s
 
c
o
n
d
u
c
t
e
d
 
d
u
r
-
in
g
 t
h
e
 2
0
0
9
 p
a
n
d
e
m
ic
 h
a
v
e
 s
h
o
w
n
 m
ix
e
d
 r
e
s
u
lt
s
—
in
 
s
o
m
e
 
s
t
u
d
ie
s
 
 
w
h
o
 
r
e
c
e
iv
e
d
 
s
t
e
r
o
id
s
 
w
e
r
e
 
m
o
r
e
 l
ik
e
ly
 t
o
 d
ie
 a
n
d
 i
n
 o
t
h
e
r
 s
t
u
d
ie
s
 
e
n
t
s
 w
e
r
e
 
n
o
 m
o
r
e
 
li
k
e
ly
 t
o
 d
ie
, 
c
o
m
p
a
r
e
d
 t
o
 
w
h
o
 d
id
 
n
o
t
 r
e
c
e
iv
e
 s
t
e
r
o
id
s
. 
A
bo
ut
 th
e 
st
ud
y 
m
ed
ic
in
e 
 
T
h
e
 
s
t
u
d
y
 
m
e
d
ic
in
e
 
is
 
a
 
li
q
u
id
. 
T
h
e
y
 
w
il
l 
b
e
 
g
iv
e
n
 
a
 
c
o
n
t
a
in
in
g
 e
n
o
u
g
h
  
m
e
d
ic
in
e
 t
o
 l
a
s
t
 f
o
r
 5
 d
a
y
s
. 
Y
o
u
r
 
p
a
r
t
n
e
r
/
r
e
l
d
 
w
il
l 
n
e
e
d
 
t
o
 
t
a
k
e
 
1
5
m
l 
b
y
 
m
o
u
t
h
 
o
n
c
e
 
a
 
d
a
y
 
fo
r
 
5
 
d
a
y
s
. 
If
 
t
h
e
y
 
a
r
e
 
t
o
o
  
 
p
o
o
r
ly
 
t
o
 
t
a
k
e
 
t
h
e
ir
 
s
t
a
n
d
a
r
d
 
t
r
e
a
t
m
e
n
t
 
b
y
 
m
o
u
t
h
, 
d
o
c
t
o
r
s
 
m
a
y
 
u
s
e
 
a
 
fe
e
d
in
g
 
t
u
b
e
 
t
o
 
g
iv
e
 
t
h
e
m
  
  
  
t
r
e
a
t
m
e
n
t
 
d
ir
e
c
t
ly
 
t
o
 
t
h
e
ir
 
s
t
o
m
a
c
h
. 
If
 
t
h
is
 
h
a
p
p
e
n
s
, 
t
h
e
 
f
e
e
d
in
g
 
t
u
b
e
 
w
il
l 
a
ls
o
 
b
e
 
u
s
e
d
 
t
o
 
g
iv
e
 
t
h
e
 
s
t
u
d
y
  
 
m
e
d
ic
in
e
. 
 If
 
y
o
u
r
 
p
a
r
t
n
e
r
/
f
r
ie
n
d
/
r
e
la
s
t
a
y
s
 
in
 
h
o
s
p
it
a
l 
le
s
s
 
t
h
a
n
 5
 d
a
y
s
 t
h
e
n
 t
h
e
y
 w
il
l 
t
a
k
e
 t
h
e
 m
e
d
ic
in
e
 h
o
m
e
 t
o
 
it
 
a
t
 
h
o
m
e
. 
T
h
e
y
 
s
h
o
u
ld
 
t
o
 
t
a
k
e
 
t
h
e
 m
e
d
ic
in
e
 a
s
 t
h
e
ir
 d
o
c
t
o
r
 t
e
ll
s
 t
h
e
m
 t
o
. 
Po
ss
ib
le
 b
en
efi
ts
 
 
W
e
 
c
a
n
n
o
t
 
p
r
o
m
is
e
 
t
h
a
t
 
t
h
e
 
s
t
u
d
y
 
w
il
l 
h
e
lp
 
y
o
u
r
 
p
a
r
t
n
e
r
/
f
r
i
v
e
, 
b
u
t
 
t
h
e
 
in
f
o
r
m
 w
e
 
g
e
t
 
f
r
o
m
 
t
h
e
 
s
t
u
d
y
 
m
ig
h
t
 
h
e
lp
 
im
p
r
o
v
e
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
 p
a
n
d
e
m
ic
 ﬂ
u
 i
n
 t
h
e
 f
u
t
u
r
e
. 
? 
 
W
e
 
w
a
n
t
 
t
o
 
lo
o
k
 
in
 
y
o
u
r
 
p
a
r
t
n
e
r
/
r
e
l
s
 
m
e
d
ic
a
l 
n
o
t
e
s
 f
o
r
 i
n
fo
r
m
a
a
b
o
u
t
 t
h
e
ir
 i
ll
n
e
s
s
 a
n
d
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
t
h
e
ir
 
d
o
c
t
o
r
 
g
iv
e
s
 
t
h
e
m
 
w
h
il
s
t
 
in
  
  
 
h
o
s
p
it
a
l.
 
T
h
e
ir
 
d
o
c
t
o
r
 
w
il
l 
g
iv
e
 
t
h
is
 
t
o
 
u
s
 
w
it
h
 
y
o
u
r
 
p
e
r
m
is
s
io
n
. 
 W
e
 w
o
u
ld
 l
ik
e
 t
o
 ﬁ
n
d
 o
u
t
 h
o
w
 y
o
u
r
 
/
f
r
ie
n
d
 
is
 
d
o
in
g
 
o
n
e
 
m
o
n
t
h
 
t
h
e
y
 
le
a
v
e
 
h
o
s
p
it
a
l.
 
W
e
 
w
il
l 
s
e
n
d
 
t
h
e
m
 
a
 
s
h
o
r
t
 
t
h
is
 
w
il
l 
t
a
k
e
 a
b
o
u
t
 5
 m
in
u
t
e
s
 t
o
 c
o
m
p
le
t
e
. 
T
h
e
 
w
il
l 
b
e
 p
o
s
t
e
d
 t
o
 y
o
u
r
 p
a
r
t
v
e
/
f
r
ie
n
d
 a
t
 t
h
e
ir
 
h
o
m
e
, 
w
it
h
 
a
 
fr
e
e
p
o
s
t
 
r
e
t
u
r
n
 
e
n
v
e
lo
p
e
. 
T
h
e
ir
/
Y
o
u
r
 
c
o
n
t
a
c
t
 
d
e
t
a
il
s
 
w
il
l 
b
e
 
s
e
n
t
 
t
o
 
t
h
e
 
C
o
  
C
e
n
t
r
e
 
in
 
N
m
 
f
o
r
 
t
h
is
 
p
u
r
p
o
s
e
. 
If
 
w
e
 
d
o
 
n
o
t
 
h
e
a
r
 f
r
o
m
 t
h
e
m
 
e
r
 a
m
e
, 
w
e
 w
il
l 
a
t
o
 c
o
n
-
t
a
c
t
 
t
h
e
m
 
b
y
 
t
e
le
p
h
o
n
e
 
t
o
 
ﬁ
n
d
 
o
u
t
 
if
 
t
h
e
y
 
h
a
v
e
  
  
 
r
e
c
e
iv
e
d
 t
h
o
n
n
a
ir
e
 a
n
d
 h
o
w
 t
h
e
y
 a
r
e
 d
o
in
g
. 
 
 
If
 
y
o
u
 
a
g
r
e
e
 
fo
r
 
y
o
u
r
 
p
a
r
t
n
e
r
/
f
r
i
v
e
 
t
o
 
t
a
k
e
 
p
a
r
t
 
in
 
t
h
e
 
s
t
u
d
y
 
t
h
e
y
 
w
il
l 
b
e
 
 
g
iv
e
n
 
s
o
m
e
 
s
t
u
d
y
 m
e
d
ic
in
e
 t
o
 t
a
k
e
 o
n
c
e
 a
 d
a
y
 f
o
r
 5
 d
a
y
s
. 
 
o
n
 w
il
l 
c
o
n
t
a
in
 e
it
h
e
r
: 
1
) 
d
e
x
a
m
e
t
h
a
s
o
n
e
 o
r
  
2)
 
a
 
p
la
c
e
b
o
 
(
a
 
d
u
m
m
y
 
t
r
e
a
t
m
e
n
t
 w
h
ic
h
 
lo
o
k
s
 
li
k
e
 t
h
e
 r
e
a
l 
m
e
d
ic
in
e
 b
u
t
 c
o
n
t
a
in
s
 n
o
 
v
e
 
in
g
r
e
d
ie
n
t
.)
  
 U
s
in
g
 
a
 
p
la
c
e
b
o
 
h
e
lp
s
 
u
s
 
m
a
k
e
 
a
 
f
a
ir
 
c
o
m
p
a
r
is
o
n
 
o
f
 
t
h
e
 
 
t
r
e
a
t
m
e
n
t
s
. 
N
e
it
h
e
r
 
y
o
u
, 
y
o
u
r
 
p
a
r
t
n
e
r
/
n
o
r
 
a
n
y
 
o
f 
t
h
e
 
d
o
c
t
o
r
s
 
o
r
 
n
u
r
s
e
s
 
lo
o
k
in
g
 
w
il
l 
k
n
o
w
 w
h
ic
h
 t
r
e
a
t
m
e
n
t
 t
h
e
y
 
a
r
e
 
r
e
c
e
iv
in
g
 
(
a
lt
h
o
u
g
h
 
if
 
t
h
e
y
 
n
e
e
d
 
t
o
 
ﬁ
n
d
 
o
u
t
 
t
h
e
y
 
c
a
n
 
d
o
 
s
o
)
. 
T
h
e
 
d
e
c
is
io
n
 
a
b
o
u
t
 
w
h
ic
h
  
  
  
 
t
r
e
a
t
m
e
n
t
 
t
h
e
y
 
r
e
c
e
iv
e
 
w
il
l 
b
e
 
d
e
c
id
e
d
 
b
y
 
c
h
a
n
c
e
 
(
r
a
t
h
e
r
 
li
k
e
 
t
o
s
s
in
g
 
a
 
c
o
in
)
 
a
n
d
 
n
e
it
h
e
r
 
y
o
u
, 
y
o
u
r
 
p
a
r
t
n
e
r
/
r
e
 o
r
 t
h
e
ir
 d
o
c
t
o
r
 w
il
l 
b
e
 a
b
le
 
t
o
  
 c
h
o
o
s
e
. 
T
h
is
 i
s
  
im
p
o
r
t
a
n
t
  
a
s
  
it
  
e
n
s
u
r
e
s
  
a
  
f
a
ir
 
Re
su
lt
s 
of
 th
e 
st
ud
y 
 
T
h
e
 r
e
s
u
lt
s
 o
f
 t
h
e
 s
t
u
d
y
 w
il
l 
b
e
 a
v
a
il
a
b
le
 
e
r
 i
t
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a
s
 
ﬁ
n
is
h
e
d
 
a
n
d
 
w
il
l 
u
s
u
a
ll
y
 
b
e
 
p
u
b
li
s
h
e
d
 
in
 
a
 
s
c
 
jo
u
r
n
a
l 
a
n
d
 
b
e
 
p
r
e
s
e
n
t
e
d
 a
t
 
a
 
 c
o
n
f
e
r
e
n
c
e
. 
H
o
w
e
v
e
r
, 
y
o
u
r
 
 
w
il
l 
n
o
t
 
b
e
 f 
t
h
e
 
r
e
s
u
lt
s
 
w
il
l 
a
ls
o
 
b
e
 
s
e
n
t
 
t
o
 
y
o
u
r
  
  
  
 
p
a
r
t
n
e
r
/
r
e
. 
 
 
W
h
e
n
 
y
o
u
r
 
p
a
r
t
n
e
r
/
f
r
ie
n
d
v
e
 
h
a
s
 
ﬁ
n
is
h
e
d
 
t
h
e
ir
 
s
t
u
d
y
 
m
e
d
ic
in
e
 
t
h
e
y
 
w
il
l 
r
e
c
e
iv
e
 
n
o
r
m
a
l 
c
a
r
e
 
w
h
il
s
t
 
in
 h
o
s
p
it
a
l.
 I
f
 t
h
e
y
 h
a
v
e
 l
 h
o
s
p
it
a
l 
a
t
 t
h
is
 p
o
in
t
 t
h
e
y
 
w
il
l 
n
o
t
 
h
a
v
e
 
t
o
 
d
o
 
a
n
y
t
h
in
g
. 
W
e
 
w
il
l 
c
o
n
t
a
c
t
 
t
h
e
m
 
w
it
h
 
a
 
e
 
o
n
e
 
m
o
n
t
h
 
t
h
e
y
 
le
a
v
e
  
 
h
o
s
p
it
a
l.
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Appendix 4 Follow-up questionnaire
 
ASAP Follow-up questionnaire Final Version 1.0 dated 23-Jul-2013 
 
 
QUESTIONNAIRE FOR YOUR COMPLETION 
 
Dear [participant name] 
 
You may remember that when you were recently admitted to hospital with a flu-like illness 
you agreed to participate in the ASAP trial – a study investigating low dose steroids in 
adults with pandemic flu. 
 
As part of this study we would like to know how you have been since you left 
hospital and would be grateful if you would complete the enclosed short 
questionnaire.  
 
Your answers to the questions are extremely valuable and will help us understand how well 
the study treatment worked. We also want to remind you that your answers will be kept 
completely confidential. Therefore, your answers will in no way affect your future 
care. 
 
 
There are no right or wrong answers. 
 
 
 
 
 
 
 
 
 
 
If you need help filling in this questionnaire, please feel free to discuss this with a relative 
or friend. 
 
We will attempt to telephone you if we have not received the questionnaire back within 14 
days. 
 
If you have any questions about this questionnaire please contact the research team at the 
co-ordinating centre on [contact number]. 
 
Thank you in advance for completing this questionnaire. 
  
INSTRUCTIONS 
 
 Please complete the enclosed questionnaire 
 Once completed, please return to the research team as soon as 
possible in the pre-paid envelope provided. 
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Participant ID no. 
 
[ID no] 
Hospital: 
 
[hospital name] 
 
ASAP Follow-up questionnaire Final Version 1.0 dated 23-Jul-2013 
 
 
Our records show that you were discharged from hospital on: 
XX-XXX-XXXX 
 
 
1. How many times have you consulted your GP for any reason in the 30 days after 
discharge from hospital? 
 
ANSWER (please tick one):  
0 □ 1□ 2□ 3□ 4□ More than 4□ times 
     If more than 4 times, how many? [      ] 
 
 
2. How many times have you been back to hospital to seek medical care in the 30 
days after discharge from hospital? 
 
ANSWER (please tick one):  
0 □ 1□ 2□ 3□ 4□ More than 4□ times      If more than 4 times, how many? [      ] 
 
 
3. Did you take your study medication home with you? 
 
ANSWER (please tick one):  
 
No   If no, there are no further questions 
 
  
Yes   If yes, please answer question 4 
  
 
4. If you answered yes to question 3, did you manage to finish the treatment course? (If 
so, the bottle containing the study medication should be empty) 
 
ANSWER (please tick one):  
 
 
 
Yes, I completed the course at home  
 
 
No, I did not complete the course  
  
 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
 
PLEASE NOW POST THIS BACK TO US USING THE PRE-PAID 
ENVELOPE PROVIDED 
APPENDIX 4
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 ASAP Relative follow-up questionnaire Final Version 1.0 dated 23-Jul-2013 
 
 
QUESTIONNAIRE FOR YOUR COMPLETION 
 
Dear [relative’s name] 
 
You may remember that when [participant’s name] was recently admitted to hospital with a 
flu-like illness you agreed for them to participate in the ASAP trial – a study investigating 
low dose steroids in adults with pandemic flu. 
 
As part of this study we would like to know how [participant’s name] has been since 
they left hospital and would be grateful if you would complete the enclosed short 
questionnaire on their behalf or forward this to them for their completion.  
 
Your answers to the questions are extremely valuable and will help us understand how well 
the study treatment worked. We also want to remind you that your answers will be kept 
completely confidential. Therefore, your answers will in no way affect your future 
care. 
 
 
There are no right or wrong answers. 
 
 
 
 
 
 
 
 
 
 
If you need help filling in this questionnaire, please feel free to discuss this with a relative 
or friend. 
 
We will attempt to telephone you if we have not received the questionnaire back within 14 
days. 
 
If you have any questions about this questionnaire please contact the research team at the 
co-ordinating centre on [contact number]. 
 
Thank you in advance for completing this questionnaire. 
  
INSTRUCTIONS 
 
 Please complete the enclosed questionnaire 
 Once completed, please return to the research team as soon as 
possible in the pre-paid envelope provided. 
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Participant ID: 
 
[participant ID] 
Hospital: 
 
[hospital] 
 
ASAP Follow-up questionnaire Final Version 1.0 dated 23-Jul-2013 
 
Please note that if you are completing this form on behalf of someone else, 
the following questions relate to that person 
 
Our records show that you were discharged from hospital on: 
[date] 
 
 
1. How many times have you consulted your GP for any reason in the 30 days after 
discharge from hospital? 
 
ANSWER (please tick one):  
0 □ 1□ 2□ 3□ 4□ More than 4□ times 
     If more than 4 times, how many? [      ] 
 
 
2. How many times have you been back to hospital to seek medical care in the 30 
days after discharge from hospital? 
 
ANSWER (please tick one):  
0 □ 1□ 2□ 3□ 4□ More than 4□ times      If more than 4 times, how many? [      ] 
 
 
3. Did you take your study medication home with you? 
 
ANSWER (please tick one):  
 
No   If no, there are no further questions 
 
  
Yes   If yes, please answer question 4 
  
4. If you answered yes to question 3, did you manage to finish the treatment course?  
    (If so, the bottle containing the study medication should be empty) 
 
ANSWER (please tick one):  
 
 
 
Yes, I completed the course at home  
 
 
No, I did not complete the course  
  
 THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
 
PLEASE NOW POST THIS BACK TO US USING THE PRE-PAID 
ENVELOPE PROVIDED 
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Appendix 5 Participating sites
i) Sites with NHS permission 
 
Blackpool Teaching Hospitals NHS Foundation
Trust  
Dr Jason Cuppitt 
Central Manchester University Hospitals NHS
Foundation Trust  
Professor Mark Woodhead 
Chelsea and Westminster Hospitals NHS
Foundation Trust   
Dr Hannah Skene 
Chesterield Royal Hospital NHS Foundation
Trust  
Dr Anthony Darby 
Countess of Chester Hospital NHS Foundation
Trust  
Dr Stephen Scott 
Derby Hospitals NHS Foundation Trust Dr Tom Bewick 
Gateshead Health NHS Foundation Trust  Dr Helen Curtis 
Heart of England NHS Foundation Trust Dr Neil Jenkins 
Hull and East Yorkshire Hospitals NHS Trust Dr Gavin Barlow 
The LeedsTeaching Hospitals NHS Foundation
Trust   
 
Dr Jane Minton 
Lothian NHS Board  Dr Adam Hill 
The Newcastle upon Tyne Hospitals NHS
Foundation Trust   
Dr Ashley Price 
Dr Frank Coffey 
Oxford University Hospitals NHS Trust Dr Matthew Scarborough 
Portsmouth Hospitals NHS Trust Professor Anoop Chauhan 
Royal Berkshire NHS Foundation Trust Dr Liza Keating 
Royal Cornwall Hospitals NHS Trust Dr Jonathan Paddle 
Royal Devon and Exeter NHS Foundation Trust  Dr Bipen Patel 
Royal Free Hampstead NHS Trust Dr Alison Rodger 
Royal Liverpool and Broadgreen University 
Hospitals NHS Trust 
Dr Andrea Collins 
The Royal Wolverhampton Hospitals NHS
Trust  
Dr Andrew MacDuff 
Sherwood Forest Hospitals NHS Foundation 
Trust 
Dr Mark Roberts 
South Tees Hospital NHS Foundation Trust Professor Stephen Bonner 
Professor Emma Baker   
University Hospitals Coventry and 
Warwickshire NHS Trust 
Dr Magdy Sakr 
University Hospitals of Morecambe Bay NHS
Foundation Trust  
Dr Asim Ijaz 
University Hospital of North Staffordshire NHS
Trust  
Dr Mohammed Haris 
Nottingham University Hospital (Queen’s
Medical Centre & City Hospital)
St George’s Healthcare NHS Trust
NHS trust Principal Investigator
Wirral University Teaching Hospitals NHS
Foundation Trust  
Dr Andrew Wight 
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ii) Sites in set-up/intending to participate  
 
  
 
 
NHS trust 
Aintree University Hospitals NHS Foundation
Trust, 
Cambridge University Hospitals NHS
Foundation Trust  
Medway NHS Foundation Trust 
NHS Grampian 
NHS Greater Glasgow and Clyde
North Bristol NHS Trust 
Salford Royal NHS Foundation Trust 
Shefield Teaching Hospitals NHS Foundation
Trust 
Southampton University Hospitals NHS Trust 
Southend University Hospital NHS Foundation
Trust  
University Hospital of South Manchester NHS
Foundation Trust  
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